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Abstract
Objectives: Pleomorphic adenoma (PA) is the most common benign salivary gland tumor.
Kallikrein-related peptidases (KLKs) have been identified as biomarkers in many human
tumors and may influence tumor behavior. We investigated KLK1-15 messenger ribonucleic
acid (mRNA) and proteins in PA specimens to determine a KLK expression profile for this
tumor.
Methods: Fresh frozen PA tissue specimens (n = 26) and matched controls were subjected to
RT-qPCR to detect KLK1-15 mRNA. Expression of KLK1, KLK12, KLK13 and KLK8
proteins were then evaluated via immunostaining techniques. Statistical analyses were
performed with the level of significance set at P < .05.
Results: We observed downregulation of mRNA expression levels for KLK1, KLK12 and
KLK13, and immunostaining studies revealed downregulation of the corresponding proteins.
Histologic evidence of capsular perforation was associated with increased KLK1 protein
expression. Tumor size was not associated with capsular invasion and/or perforation.
Conclusions: This study is the first to detail a KLK expression profile for PA at both the
transcriptional level and the protein level. Future work is required to develop clinical
applications of these findings.
Keywords: Pleomorphic adenoma, salivary gland tumors, kallikrein-related peptidases,
kallikreins, immunohistochemistry, biomarkers
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Chapter 1

1

Introduction

1.1 Salivary gland development and function
1.1.1

Role of salivary glands

Salivary glands are exocrine glands that secrete saliva. This fluid substance performs a
wide array of physiologic and protective functions. Being a liquid, saliva lubricates the oral
cavity and protects the teeth and surrounding soft tissues, which is crucial for speech and
the perception of food taste [1]. Although mostly composed of water, saliva contains
numerous electrolytes and proteins fulfilling a variety of functions. The high bicarbonate
concentration of saliva buffers acids produced by plaque bacteria thereby helping to
prevent tooth decay. Saliva also serves to protect the mucosal lining of the mouth via an
array of antimicrobial agents including immunoglobulin A, lysozyme and lactoperoxidase.
Saliva is also important for the initiation of starch and lipid digestion through a-amylase
and lipase enzymes, respectively. A litany of growth factors and other small peptides are
also secreted, many of which have unknown functions [2, 3]. When salivary production is
impaired¾a condition known as xerostomia¾the paramount importance of saliva
becomes evident. Patients with xerostomia suffer from oral infections, dental caries,
mastication and swallowing problems, loss of taste (dysgeusia), and pain/discomfort during
eating or talking.

1.1.2

Structures and cell types of adult salivary glands

The various salivary glands (i.e., parotid, submandibular, sublingual, and minor salivary
glands) are complex networks of secretory units and hollow tubes, each having individual
specificities of function based on their location. Mature adult salivary glands are comprised
of glandular secretory tissue known as parenchyma, and a supporting connective tissue
stroma [4]. A network of ducts connects the secretory units of the parenchyma to the oral
cavity. These secretory units are classified as either mucous, serous, or seromucous,
depending on the composition of their secretions. Mucous secretions are composed mainly
of glycoproteins, which are complex carbohydrates attached to mucin proteins. Serous
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secretions have a considerable amount of protein but very few mucin proteins. Seromucous
secretions are a blend of serous and mucous secretions. The salivary acini produce
secretions with variable composition; serous secretions are watery, whereas mucous
secretions are viscous and provide more of the lubricant properties to saliva.
On histologic examination of salivary tissue, serous cells and mucous cells may be easily
differentiated [4]. Serous cells are pyramidal in shape and form spheroidal clusters, or
acini. These cells display a large, round central nucleus and small apical granules that stain
darkly with haematoxylin. On the other hand, mucous cells are columnar and develop in
elongated tubular clusters. Mucous cells contain large and closely-packed granules in their
apical two-thirds, which displace and flatten the nucleus at the base of the cell. Resultantly,
the apical cytoplasm stains poorly with haematoxylin-eosin. Secretions from these
secretory units are released by consecutive progression through intercalated ducts, striated
ducts, excretory ducts and, finally, the main excretory duct that opens into the oral cavity.
The ducts are impermeable to water, with intercalated ducts being lined by small cuboidal
cells, striated ducts lined by columnar cells (arranged in a simple or pseudostratified
manner), and excretory ducts lined by stratified columnar epithelium. Though
impermeable, the ionic content of saliva is actively modified in the striated ducts. To trigger
discharge of the contents of secretory cells, there is a contraction of myoepithelial cells,
which surround the acinar units and ducts. Furthermore, each adult salivary gland is
associated with nerves, blood vessels and a fibrous connective tissue capsule. The capsule
divides the parenchyma into lobules by septa projecting into the gland. Intercalated and
striated ducts are found inside lobules, while excretory ducts are located within connective
tissue septa between lobules.

1.1.3
1.1.3.1

Major salivary glands
The parotid gland

In human embryogenesis, each of the paired parotid glands begins development as a
thickening of the epithelium in the cheek of the oral cavity [5]. This thickened area, which
forms around the time the embryo has reached 15 mm in crown-to-rump length, extends
posteriorly towards the ear in a plane superficial to the developing facial nerve. Around the
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third month of intrauterine life, bud-like projections extend from the deep aspect of the
parotid gland and envelope the branches of the facial nerve. Once these projections merge,
the deep lobe of the gland has formed. Ultimately, the parotid gland becomes a bi-lobed
structure with a larger superficial lobe (80% of gland) and a smaller deep lobe (20% of
gland) [6]. The isthmus connecting these lobes crosses branches of the facial nerve [6].
Between the lobes, the branches of the facial nerve are invested in loose connective tissue,
an important observation for surgical interventions in this region. The parotid gland, which
is the largest of the major salivary glands, has completely formed by the sixth month of
intrauterine life and is composed entirely of serous acini.
Anatomically, the parotid gland occupies the space between the posterior border of the
mandibular ramus and the mastoid process of the temporal bone. Superior to the gland lies
the external acoustic meatus, the glenoid fossa of the temporomandibular joint (TMJ), and
the zygomatic arch. Structures deep (medial) to the gland include the styloid process of the
temporal bone. Inferiorly, the tail of the parotid overlaps the mandibular angle, and the
deep surface of the gland overlies the transverse process of the atlas (first cervical vertebra,
C1). On average, the gland is triangular in shape and spans 6 cm in length, with a maximum
of 3.3 cm in width [7]. Occasionally, a small accessory lobe, which arises from the upper
border of the parotid duct, can be found crossing over the zygomatic arch.
A fibrous capsule envelops the parotid gland. The deep layer of the capsule is a
continuation of the deep cervical fascia, which attaches to the mandible and to the temporal
bone at the tympanic plate, styloid process and mastoid process [8]. The superficial layer
of the capsule is formed as part of the superficial musculo-aponeurotic system (SMAS) and
appears to be continuous with the fascia overlying the platysma muscle [9]. In the anterior
region, a separate layer forms over the masseteric fascia, which is itself an extension of the
deep cervical fascia. Between these two fascial layers, the parotid duct and the peripheral
branches of the facial nerve are found. Superiorly, the parotid gland is closely molded
around the external acoustic meatus and the TMJ. There is an avascular plane between the
medial parotid capsule and the cartilaginous and bony acoustic meatus. Inferiorly, the apex
of the gland reaches the angle of the mandible and often extends to overlap the digastric
triangle and posterior pole of the submandibular gland. The anterior and posterior parotid
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gland borders overlap the posterior border of the masseter muscle and the anterior border
of the sternocleidomastoid muscle, respectively [5].
Important structures emerge from the parotid gland¾the parotid duct, branches of the
facial nerve, and blood vessels. The parotid duct, or Stensen’s duct, exits at the anterior
border of the parotid gland and runs horizontally across the masseter muscle before
piercing the buccinator muscle to end at the intraoral parotid papilla. Branches of the facial
nerve exit the anterior border of the parotid gland and extend to the various muscles of
facial expression. At the superior border of the gland, the superficial temporal vessels are
oriented such that the artery is anterior to the vein. Deep to these vessels, the
auriculotemporal branch of the mandibular nerve is found. Running parallel to the parotid
duct at a level 1 cm superiorly is the transverse facial artery (a branch of the superficial
temporal artery). Some terminal branches of the great auricular nerve lie superficial to the
gland [5].
Lymph nodes associated with the parotid gland, known as preauricular nodes, are located
within the overlying subcutaneous tissues and within the parenchyma of the gland [10].
Typically, there are 10 nodes within the parenchyma; the majority are in the superficial
lobe, which is superficial to the plane of the facial nerve. Only one or two nodes are
distributed within the deep lobe [11]. Collectively, the preauricular nodes drain into the
upper deep cervical chain.
Parasympathetic secretomotor innnervation of the parotid gland comes from the inferior
salivatory nucleus in the brain stem. From this starting point, the nerve fibers travel along
the tympanic branch of the glossopharyngeal nerve, contributing to the tympanic plexus in
the middle ear. The lesser petrosal nerve branches off from the temporal plexus and runs
in a groove in the petrous temporal bone in the middle cranial fossa. It eventually reaches
the otic ganglion, which lies on the medial aspect of the mandibular branch of the
trigeminal nerve, by exiting the cranium through the foramen ovale. Postsynaptic
postganglionic fibers leave the otic ganglion to join the auriculotemporal nerve. The
auriculotemporal nerve then distributes the parasympathetic secretomotor fibers
throughout the parotid gland [5, 8, 9].
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Sympathetic innervation of the parotid gland stems from the superior cervical sympathetic
ganglion. Fibers project to the gland from the sympathetic plexus around the middle
meningeal artery. These fibers then pass through the otic ganglion without synapsing and
innervate the gland via the auriculotemporal nerve. Further sympathetic innervation is
derived from plexuses associated with surrounding blood vessels supplying the gland [8,
9].
Sensory fibers originating in the parotid gland connective tissue first merge with the
auriculotemporal nerve then pass through the otic ganglion without synapsing. Afterwards,
these fibers join the mandibular division of the trigeminal nerve. Sensory innervation of
the parotid capsule is provided by the great auricular nerve [5, 8, 9].

1.1.3.2

The submandibular gland

Formation of the paired submandibular glands is initiated at 13 mm of crown-to-rump
length as an epithelial outgrowth into the floor-of-mouth mesenchyme occupying the
linguogingival groove [5]. Rapid proliferation of this tissue occurs, giving off many
branching processes, which eventually develop lumina. Before reaching its destination
below the tip of the tongue, the duct orifice opens into the floor of the mouth on either side
of the lingual frenum. The walls of the groove into which the orifice drains merge together
to form a duct-like structure (i.e., Wharton’s duct), and this process commences in a
posterior-to-anterior fashion until the final orientation is achieved.
Anatomically, the submandibular gland is comprised of a larger superficial lobe, which
occupies the digastric triangle in the neck, and a smaller deep lobe, which lies in the
posterior floor of the mouth region. There is no discontinuity between the lobes; rather, the
gland wraps around the posterior border of the mylohyoid muscle to give the appearance
of two lobes [12]. The submandibular gland comprises both serous and mucous acini.
Within the digastric triangle lies the superficial lobe. The anterior pole of the lobe reaches
the anterior belly of the digastric muscle, and the posterior pole extends to the
stylomandibular ligament. The stylomandibular ligament is all that separates the superficial
lobe of the submandibular gland from the parotid gland. Superiorly, the superficial lobe is
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medial to the mandibular body, while the inferior aspect of the lobe overlaps the
intermediate tendon of the digastric muscles and the insertion of the stylohyoid muscle.
Two layers of the deep cervical fascia envelop the superficial lobe and join at the greater
cornu of the hyoid bone. The superficial fascial layer is attached to the lower border of the
mandible and covers the inferior surface of the superficial lobe. The deep fascial layer is
attached to the mylohyoid line on the inner aspect of the mandible and thus covers the
medial aspect of the lobe. Covering the inferior surface of the lobe are multiple layers, from
superficial to deep, consisting of: skin, subcutaneous fat, platysma muscle, and deep
cervical fascia. The facial vein and the cervical branch of the facial nerve cross the
superficial lobe at the inferior surface. Between the gland and the mandibular body are the
submandibular lymph nodes. Rarely, one or more lymph nodes may be embedded within
the salivary gland [5]. The lateral surface of the superficial lobe is related to the
submandibular fossa¾a depression on the medial aspect of the mandible¾and the
attachment of the medial pterygoid muscle. The facial artery courses from the deep aspect
of the lobe along the lateral surface of the gland until it wraps around the inferior border of
the mandible. The medial and posterior surfaces of the superficial lobe are related to the
mylohyoid muscle and the styloglossus muscle, respectively.
The deep lobe of the gland arises from the superficial lobe as it wraps around the posterior
free edge of the mylohyoid muscle and extends anteriorly towards the sublingual gland
[13]. Many structures surround the deep lobe, including the mylohyoid muscle
inferolaterally, the hyoglossus muscle and the styloglossus muscle medially, the lingual
nerve superiorly, and the hypoglossal nerve and deep lingual vein inferiorly. Of note, the
submandibular duct, which arises from the superficial lobe, rests on the lateral surface of
the hyoglossus muscle inferior to the lingual nerve and superior to the hypoglossal nerve.
The lingual nerve loops laterally to medially around the duct at the anterior border of the
hyoglossus muscle. Blood supply to both lobes of the submandibular gland arises from
multiple branches of the facial and lingual arteries. Venous blood drains into the deep
lingual vein and lymphatic drainage proceeds into the deep cervical lymph nodes,
predominantly into the jugulo-omohyoid node by way of the submandibular nodes [14].
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The parasympathetic secretomotor supply to the submandibular gland is derived from the
submandibular ganglion, a small ganglion resting at the superior aspect of the hyoglossus
muscle [15, 16]. This ganglion is suspended from the lingual nerve by anterior and
posterior filaments. Tracing back to their origin in the brainstem, parasympathetic
secretomotor fibers originate in the superior salivatory nucleus. The preganglionic fibers
travel to the submandibular ganglion via the facial nerve, chorda tympani and the lingual
nerve in succession. The posterior filaments branching from the lingual nerve synapse in
the ganglion before sending off postganglionic fibers to the submandibular and the
sublingual glands. Some fibers are even believed to reach the lower pole of the parotid
gland [5, 13].
Sympathetic innervation of the submandibular gland arises from the sympathetic plexus on
the facial artery. The postganglionic fibers stemming from the superior cervical ganglion
pass through the submandibular ganglion without synapsing and provide vasomotor control
to the submandibular and the sublingual glands. Some branches terminate in the
submandibular gland and Wharton’s duct via the posterior filament, while others pass back
into the lingual nerve via the anterior filament to ultimately innervate the sublingual gland
and local minor salivary glands. Finally, sensory fibers originating in the submandibular
gland and the sublingual gland pass through the submandibular ganglion without synapsing
to join the lingual nerve.

1.1.3.3

The sublingual gland

Development of the paired sublingual glands during human embryogenesis begins at 20mm crown-to-rump length as numerous small epithelial thickenings in the linguogingival
groove [5]. Canalization of each epithelial thickening occurs, which places many of the
sublingual duct openings directly atop the sublingual fold [15, 16]. Ducts that form within
the linguogingival groove drain into the submandibular duct. It is not uncommon for a
collection of draining ducts to coalesce anteriorly to form a major duct (i.e., Bartholin’s
duct), which opens at the sublingual papilla along with the orifice of the submandibular
duct (i.e., Wharton’s duct) [15].
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Being the smallest of the major salivary glands, the sublingual gland is almond-shaped and
weighs only 4 grams [5]. This gland lies on the mylohyoid muscle and is covered by the
floor-of-mouth mucosa. The mucosa overlying the gland forms the sublingual fold. At its
posterior aspect, the sublingual gland contacts the deep lobe of the submandibular gland.
The bilateral sublingual gland fossae are located in the anterior mandible lateral to the
genial tubercles. Medial to the gland, between it and the genioglossus muscle, are found
the lingual nerve and the submandibular duct. In terms of its secretory units, the sublingual
gland is comprised predominantly of mucous acini [15].
Blood supply to the sublingual gland is from the sublingual and the submental branches of
the lingual and the facial arteries, respectively. Innervation is via the submandibular
ganglion as described in Section 1.1.3.2. Lymphatic drainage flows to the submental lymph
nodes.

1.1.4

Minor salivary glands

Minor salivary glands are found throughout the oropharynx and oral cavity, mainly
grouped as labial, buccal, palatoglossal, palatal, and lingual glands [5]. Depending on the
location, each cluster of glands has a distinct ratio of serous-to-mucous acini. For example,
the labial and buccal glands contain both mucous and serous acini, whereas the
palatoglossal glands contain only mucous acini. Distributed throughout the hard and soft
palate are palatal glands, which release mucous secretions. The anterior lingual glands have
mainly mucous acini and they drain via four to five ducts on either side of the lingual
frenum. The posterior lingual glands are near the root of the tongue and they also release
mainly mucous secretions. Glands that have predominantly serous acini include the deep
posterior lingual glands and the glands of von Ebner at the circumvallate papillae on the
dorsum of the tongue. The watery, serous secretions are thought to help spread taste stimuli
over the taste buds.
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1.2
1.2.1

Pleomorphic adenoma
Background

Pleomorphic adenoma (PA), also known as benign mixed tumor, is the most common
salivary gland neoplasm in all age groups [17]. This tumor accounts for approximately
60-70% of all salivary gland neoplasms, is most common in adults between the ages of 30
and 60, has a slight female predilection, and has a high recurrence rate; however, with
adequate surgery, a cure rate of more than 95% is achievable [18-20]. Surgical treatment
of PA by superficial parotidectomy results in decreased recurrence rates compared to
simple enucleation of the tumor [17]. It is important to note that malignant transformation
to carcinoma ex pleomorphic adenoma occurs in 5% to 10% of cases, making carcinoma
ex PA the fourth most common malignant salivary gland tumor. Pleomorphic adenoma has
a predominant stromal component but is not truly a mixed neoplasm derived from more
than one germ layer; it is purely of epithelial origin. This tumor has a variable histologic
appearance, containing luminal-type ductal epithelial cells, myoepithelial cells and a
stroma-like background tissue with mucoid, myxoid or chondroid features [21, 22].
Cytogenetic analysis has shown translocations in pleomorphic adenoma gene 1 (PLAG1)
located at chromosome region 8q12 in approximately 70% of PAs [19].
Pleomorphic adenoma arises in the parotid gland in about 80% of cases, particularly in the
tail and inferior aspect of the gland. Other locations include the submandibular gland
(~10%), minor salivary glands (~10%), and the sublingual gland (0.3-1%). For minor
salivary gland PAs, the most common site is the palate (60%), followed by the lip (20%)
and buccal mucosa (10%) [19, 23]. Development of intraosseous PA has been reported but
is exceedingly rare [24]. Further still, cases of PA arising in the external auditory meatus
[25], cervical lymph nodes [26], thyroid isthmus [27], lacrimal gland [23], breast [28],
vulva [29], and sella turcica [30] have been documented.

1.2.2

Clinical features and gross appearance

Pleomorphic adenoma is a benign, slowly growing neoplasm that often presents as a
painless, firm and mobile mass. This growth is a circumscribed, encapsulated and often
lobulated tumor with a fibrous capsule of varying thickness. Facial nerve palsy and pain
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are exceedingly rare with PA. In about 10% of cases, PA will present in the deep lobe of
the parotid, resulting in a parapharyngeal mass. Palatal PAs commonly arise at the soft
palate-to-hard palate junction. When found in the hard palate, PA will not be mobile due
to proximity to the mucoperiosteum. A recurrent PA will also be fixed rather than mobile.
Most often, a PA will present as a solitary tumor; however, this tumor may be synchronous
or metachronous with other salivary gland tumors (e.g., Warthin’s tumor, mucoepidermoid
carcinoma [MEC], acinic cell carcinoma [ACC], or adenoid cystic carcinoma [AdCC])
[31-33].

1.2.3

Histopathology

Pleomorphic adenoma is of epithelial origin and consists of a mixture of myoepithelial
cells and ductal cells within a mesenchymal background. The cells of mesenchymal
appearance have been described as a combination of stromal cells and metaplastic
myoepithelial cells [18]. Occasionally, sebaceous, mucinous and serous acinar cells can be
seen within the tumor but these are usually found at the periphery where residual acinar
structures have been entrapped within the growing mass [34, 35]. The stromal cells in PA
have also been identified as interdigitating dendritic cells [18]. As previously mentioned,
PA is encapsulated by a layer of fibrous tissues of varying thickness. This capsule is
considered a pseudocapsule, which forms secondary to compression and atrophy of
adjacent NSGT. The pseudocapsule may be poorly developed and/or absent in some areas,
particularly in tumors having a significant mucoid/myxoid component, or in minor salivary
gland tumors. Such a breach or perforation of the capsule is a common finding, as is
invasion of neoplastic cells into the capsule; however, these capsular violation phenomena
should not be confused with malignancy arising within a PA. Partial lack of a capsule is a
feature found in both PA and myoepithelioma.
Pleomorphic adenoma is rarely multifocal. The multifocal histologic appearance
commonly observed is often artefactual, produced by cross-sectional cuts that bisect fingerlike protrusions of the nodular tumor. The neoplastic myoepithelial cells of PA have a
morphology that differs from the typical flattened or stellate myoepithelial cells
surrounding normal acini and intercalated ducts. The ductal epithelial cells are often
cuboidal and form duct-like structures consisting of inner ductal epithelial elements with
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or without surrounding layers of abluminal myoepithelial cells. These myoepithelial cells
surrounding duct-like structures may be spindle-shaped, epithelial or clear cell in
appearance, which is a feature of PA, epithelial-myoepithelial carcinoma and some AdCCs.
The stroma is predominantly mucoid/myxoid and chondroid but may also appear
hypocellular and rich in vascularity, or fibrous and hyalinized. For the most part, longstanding tumors demonstrate increased hyalinization of the stroma. The chondroid stromal
component of PA is true cartilage, which is positive for type II collagen and keratin sulfate.
The majority of PAs have variable stromal elements consisting of the aforementioned
types, with very few tumors having a uniform stromal composition.
The epithelial components of PA have variable cellularity both within tumors and between
tumors. In one-third of PAs, there is an equal distribution of cellular and stromal elements;
of the remaining two-thirds, approximately one-third have predominantly stromal elements
and the remaining one-third have predominantly cellular elements. The cellular variants
commonly occur in PA that arises in minor salivary gland tissue. Of note, there are no
known correlations between cellularity and recurrence and/or malignant transformation.
The most common variant of mesenchyml stroma is mucoid/myxoid followed by
chondroid stroma. A transition zone is often observed between myoepithelial cells and the
mesenchyme-like tissue, which suggests that metaplasia of the former occurs during tumor
formation/growth [18].
Squamous metaplasia is a feature common to some salivary gland lesions, including PA
and necrotizing sialadenitis. It usually presents in larger ducts but may also be found as
sheets of epidermoid tissue with or without keratin pearls. A foreign body reaction may be
present in response to the keratin or a previous fine needle aspiration (FNA) procedure.
The squamous metaplasia can be extensive, affecting up to 95% of the epithelial
component of PA. Pleomorphic adenoma with such metaplastic changes can easily be
confused with MEC [36-38]. A diagnosis of PA, rather than MEC, will be supported by a
low Ki-67 labeling index and a positive myoepithelial profile (S-100, vimentin and smooth
muscle actin [SMA]). Previous estimates state that squamous metaplasia may occur in
approximately 25% of PAs [21], but the incidence may now be greater due to the more
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widespread use of FNA. Squamous metaplasia may be found in almost any salivary gland
tumor that has been exposed to preoperative FNA.
Oncocytic metaplasia may be present within PA as focal changes but is not as common as
squamous metaplasia. A misdiagnosis of oncocytoma may be made on the rare occasion
that nearly the entire PA is affected. For a lesion to be correctly classified as an
oncocytoma, it must consist exclusively of oncocytic cells. The transformation of PA
epithelial cells into oncocytic cells occurs by a process of re-differentiation rather than by
degeneration, as once believed [18]. In tumors with extensive oncocytic metaplasia and
clear cell change, a PA may be misdiagnosed as an ACC. Staining an oncocytic ACC with
periodic acid-Schiff (PAS) solution reveals cytoplasmic granules; these granules are
resistant to diastase digestion. This is an important differentiating technique, since the
oncocytic cells in non-ACC tumors are not resistant to diastase. Furthermore, oncocytic
cells in PA will not react with phosphotungstic acid-haematoxylin (PTAH) stain and will
be amylase negative, whilst the opposite is true for ACC.
Lipometaplasia in PA can occur but does so infrequently. In fact, cases with extensive
lipometaplasia have recently been described as a subtype of PA, the so-called lipomatous
PA (LPA) [39-41]. In LPA, there is a lipomatous stromal component affecting more than
90% of the tumor tissue; these lipocytic cells are evenly distributed throughout the tumor.
A differential diagnosis may include: lipoadenoma, sialolipoma, spindle cell lipoma,
interstitial lipomatosis, and lipomatous atrophy. The lipocyte formation is thought to result
from lipid accumulation in the myoepithelial cells of PA, which has been confirmed by
ultrastructural studies showing lipid droplets within otherwise unremarkable myoepithelial
cells [41, 42].
In performing histologic examination of parotid gland tumors, parotidectomy specimens
and large incisional biopsies often provide sufficient tissue to reach the diagnosis of PA.
The differential diagnosis for these tumors includes PA with atypical features and
intracapsular carcinoma ex PA. Tumors arising from minor salivary glands, particularly
within the oral cavity, shift the differential diagnosis to include myoepithelioma,
polymorphous low-grade adenocarcinoma (PLGA) and AdCC. The features that
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distinguish myoepithelioma from PA are the relative lack of ductal structures and
myxochondroid/chondroid areas, although there is little clinical relevance to these
differences. Myxoid stroma is often present in myoepithelioma but to a lesser extent than
that found in PA. It is important to differentiate between malignant tumors (e.g., PLGA
and AdCC) and PA since the treatment plans vary significantly. The most important feature
of PA that differs from these two malignant tumors is the presence of a capsule; however,
PA may have small areas that lack encapsulation as previously discussed. Accordingly, a
nonencapsulated tumor in a smaller biopsy specimen does not rule out PA. Pleomorphic
adenoma does not display the typical malignant histopathological findings such as cellular
atypia, invasive growth pattern with perineural growth, single-file arrangement of cells (as
seen in PLGA), or the ‘bluish’ appearance of stroma and luminal content observed in
AdCC.

1.2.4

Atypical features and malignant counterparts to PA

Some of the atypical histopathological features exhibited by a small number of PAs include
hyalinization, hypercellularity, cellular anaplasia, necrosis and capsular violation [43].
When one or more of these atypical features are present, the tumor is classified as an
atypical pleomorphic adenoma (APA), which is distinguished from non-invasive
carcinoma ex PA [18]. To differentiate atypical hyalinization from the intercellular
trabecular hyaline structures found in many PAs, the pathologist must identify prominent
zones of hyalinized stroma with scarce epithelial cells. On the other hand, hypercellularity
is defined as densely cellular zones in which little intercellular stroma is evident. Cellular
anaplasia can be identified by an increased number of mitoses along with foci of tumor
cells with enlarged, hyperchromatic and pleomorphic nuclei. Necrosis in APA appears as
focal areas of necrotic debris and reactive, atypical cells secondary to trauma by FNA; this
contrasts to the extensive areas of necrosis seen in infarcted PA. Capsular violation, which
is evident by tumor cells invading into or perforating through the fibrous capsule, is not
sufficient by itself to make the diagnosis of APA. Malignant transformation to carcinoma
ex PA is more common among PAs with atypical features (i.e., APAs) than conventional
PAs [44]. In fact, the only histopathological feature significantly correlated with malignant
transformation is hyalinization [44].
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The malignant counterparts to PA include metastasizing PA, carcinoma ex PA and
carcinosarcoma. Metastasizing PA is a rare entity classified as a histologically benign PA
with an inexplicable manifestation as local or distant metastases [45-47]. This disease is
lethal in approximately 30% of cases despite the benign nature of the metastatic deposits
[18]. Metastatic lesions have been reported mainly in the bone, lung, lymph nodes, oral
cavity, skin, liver, retroperitoneum, kidney, brain and sphenoid sinus. Bone is the most
frequently observed location for PA metastases, affecting approximately 50% of reported
cases. Nearly 30% of cases have metastatic deposits in the lymph nodes and the lung [45].
In most cases, incomplete primary surgery or enucleation leading to multiple recurrences
appears to be a prerequisite for metastatic PA; however, previous surgical intervention is
not required as genetic mutations may be responsible for the occurrence of some cases of
metastatic disease [48-68]. The disease carries considerable morbidity and mortality with
5-year disease-specific and disease-free survival of 58% and 50%, respectively [69].
Consequently, the reclassification of metastatic PA as a low-grade malignancy has been
debated [70, 71]. There are no existing histopathological parameters that can be used to
predict the development of PA metastases.
Malignant transformation to carcinoma ex PA occurs in approximately 5-10% of PAs,
mostly in long-standing tumors with multiple recurrences [72]. Carcinoma ex PA
commonly presents as a poorly differentiated adenocarcinoma (e.g., salivary duct
carcinoma), but other patterns also can develop, including myoepithelial carcinoma,
PLGA, MEC, and AdCC [19]. Areas of typical benign PA may be found to occupy most
or only a small portion of the lesion. Within the tumor, areas of malignant degeneration of
the epithelial component are demarcated by cellular pleomorphism and abnormal mitotic
activity. Based on the pattern of growth, carcinoma ex PA can be divided into three
subcategories: invasive, minimally invasive, or non-invasive. Invasive carcinoma ex PA
shows malignant cells penetrating greater than 1.5 mm into the extracapsular tissues [72].
Non-invasive (no violation of tumor capsule) carcinoma ex PA and minimally invasive
(<1.5 mm of extracapsular extension) carcinoma ex PA may be considered as ‘early’
lesions, but their clinical relevance is not fully understood [72-74]. Carcinoma ex PA is
the fourth most common salivary gland malignancy after MEC, AdCC, and ACC. Since
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salivary duct carcinoma is frequently the malignant component in carcinoma ex PA, it may
be more accurate to denote carcinoma ex PA as the fifth most common salivary gland
malignancy (after salivary duct carcinoma).
The carcinosarcoma is the rarest malignant counterpart to PA. This tumor presents most
commonly in the parotid gland, but it may also occur in the submandibular gland and minor
salivary glands. Clinically, carcinosarcoma behaves similarly to carcinoma ex PA. Some
carcinosarcomas display evidence of an origin from a benign PA; however, a previous
history of benign PA is not a prerequisite for this tumor as cases may arise de novo.
Histologic assessment of carcinosarcoma reveals a biphasic tumor comprising both
carcinomatous and sarcomatous areas. The epithelial component may consist of an
undifferentiated carcinoma or a poorly differentiated adenocarcinoma.

1.2.5

Treatment and prognosis

Complete surgical excision of PA is curative in a clear majority of cases. For parotid PA,
the treatment of choice is either superficial or total parotidectomy for lesions in the
superficial lobe or deep lobe, respectively. Superficial lobe PA may be treated by partial
superficial parotidectomy, which involves excision of the tumor along with a 2 cm margin
of normal parenchyma except at the point where the tumor abuts the facial nerve [75]. As
compared to complete superficial parotidectomy, partial superficial parotidectomy is
associated with a lower incidence of transient facial nerve dysfunction, facial contour
disfigurement, and subsequent Frey’s syndrome [75]. Excision of the entire submandibular
or sublingual gland is performed for PA in these areas, but complete excision is not always
readily performed for certain minor salivary glands. When removed in its entirety, PA will
not recur; however, unsatisfactory surgery poses a high risk for recurrence due to residual
tumor left behind or tumor spillage and seeding at the operative site. Postoperative
radiotherapy is not necessary for histologically benign tumors but is occasionally employed
for controlling subclinical disease in patients at high risk of recurrent/persistent disease
[76]. The small risk for malignant transformation of recurrent/persistent PA is also
increased with unsatisfactory surgery. The variable recurrence rates reported in the
literature are mainly a function of the highly technique-sensitive nature of parotid gland
surgery. Total parotidectomy provides the lowest recurrence rates but often necessitates
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sacrifice of the facial nerve, which results in unnecessary postoperative morbidity. When
performed by an experienced surgeon, partial superficial parotidectomy may provide
comparable recurrence rates to complete superficial parotidectomy and total parotidectomy
without the accompanying risks to facial nerve function.
Surgical management of the malignant counterparts to PA is variable. For invasive
carcinoma ex PA, wide excision is performed, occasionally in conjunction with local
lymph node dissection and adjunctive radiotherapy. The 5-year survival rate ranges from
25% to 65%, but this plummets to 10% to 35% at 15-years; however, the prognosis
ultimately hinges upon the histopathological subtype of the malignant component [19]. For
example, well-differentiated carcinomas such as PLGA have nearly a 90% 5-year survival
rate, while patients with poorly-differentiated tumors or extracapsular invasion beyond 8mm have a much worse outlook [76]. The prognosis for non-invasive or minimally invasive
carcinoma ex PA approximates that for benign PA. Metastasizing PA is managed by
surgical excision of both the primary tumor and the metastatic sites, with a mortality rate
approaching 40% [19, 76]. Carcinosarcoma is managed by radical surgical excision with
occasional adjuvant radiation therapy and/or chemotherapy. The prognosis for
carcinosarcoma is the worst of the malignant counterparts to PA, with up to 75% of patients
developing recurrent or metastatic disease.

1.3 Human tissue kallikrein and kallikrein-related peptidases
1.3.1

Background

Kallikrein-1 (KLK1) and the remaining kallikrein-related peptidases (KLK2-15) are a
family of fifteen homologous secreted serine endopeptidases [77-79]. As the first of the
family to be studied, KLK1 was identified to be involved in blood pressure regulation
through its kininogenase activity (80). More recent research has determined that other
KLKs are involved in a wide range of physiological processes, such as skin desquamation,
semen liquefaction, regulation of immune response, and enamel formation [78, 81, 82].
Moreover, studies have revealed that dysregulation of KLK expression, activity or
localization is frequently associated with pathological disorders, such as respiratory
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diseases, skin pathoses, perturbation of tooth enamel formation, neurological disorders, and
carcinogenesis [81-89].
This peptidase family gained notoriety in the field of cancer research with the discovery of
the correlation between serum KLK3 (prostate-specific antigen [PSA]) levels and prostate
cancer [90]. Prostate-specific antigen is a useful biomarker for the diagnosis, staging and
monitoring of prostate cancer, but its utility in prostate cancer screening is questionable
[91]. The expression of KLKs in other diseases has been investigated to extend their use
as diagnostic and/or prognosticating biomarkers [92-96]. Numerous studies have
highlighted the functional involvement of KLKs in carcinogenesis, in that KLKs are
secreted into the tumor microenvironment where they may positively or negatively
modulate disease progression [88]. For example, they control the growth of cancer cells by
regulating the bioactivity of several hormones and growth factors through cell surface
receptor activation [97]. Furthermore, KLKs promote cancer cell migration and invasion
due to their proteolytic action on extracellular matrix (ECM) proteins [98]; they also
regulate interactions between cancer cells and other cells in the tumor microenvironment,
such as osteoblasts, fibroblasts and endothelial cells [99-102]. Due to this functional role
of KLKs in cancer progression, researchers have investigated their utility as therapeutic
targets to counteract tumor progression [81, 94, 103].

1.3.2

KLKs at the transcriptional level

The KLK family locus (italicized abbreviation, KLK, denotes the kallikrein genes) is
comprised of fifteen genes in a tandem cluster on the long arm of human chromosome
19q13.3-13.4. This cluster is the largest contiguous sequence of protease encoding genes
in the human genome [103]. All fifteen KLK genes, KLK1-15, comprise five exons, which
have highly conserved structures but lengths varying between 4.3 and 10.5 kb. The start
codon and a short 5’-UTR (untranslated region) is always contained within the first exon,
while the stop codon, poly-A tail and 3’-UTR are all located in exon 5. The serine-type
catalytic triad of KLKs is formed by three residues: histidine, His57; aspartic acid, Asp102;
and serine, Ser195, which are conserved in KLK1-15 and are encoded by exons 2, 3 and 5,
respectively [78, 88]. On the other hand, non-coding KLK regions are more variable

18

resulting in the observed gene length differences (i.e., 4.3-10.5 kb). Moreover, the intron
sequences vary to a significant extent, which could explain differences in the regulatory
mechanisms of individual KLKs [78, 88].
The regulation of KLKs¾where the non-italicized abbreviation, KLK, denotes kallikrein
proteins¾by steroid hormones is well understood, and aberrant KLK expression in cancer
tissues is well documented [77, 78, 88, 104]. On the other hand, less is known about the
transcriptional regulation of KLKs. Hormone-dependent tissues such as breast, ovary and
prostate have been shown to regulate KLK expression through trans-activating factors
including androgens, estrogens, glucocorticoids and progestins [105-109]. Researchers
have identified associations between KLK mRNA upregulation and increased levels of
interleukins (IL) (e.g., IL-1 and IL-6) during skin inflammation [86]. Other factors found
to modulate KLK expression include vitamin D, thyroid hormone and retinoic acid [89]. A
group of investigators recently determined that KLK12 expression in lung cancer cell lines
is regulated by tissue hypoxia, which suggests involvement of KLK12 protein in
angiogenesis [99]. Specific DNA sequence mutations, known as single nucleotide
polymorphisms (SNPs), occur in more than 1% of the population and have been identified
within the KLK locus [84]. These SNPs have been shown to modulate kallikrein expression
at the transcriptional level and at the protein level, affecting proteolytic activity of secreted
KLKs [110-113].

1.3.3

KLKs at the protein level

Kallikrein proteins are secreted as trypsin-like (e.g., KLK1, KLK2, KLK4-6, and
KLK8-14) or chymotrypsin-like (e.g., KLK3, KLK7, KLK9, and KLK15) serine
endopeptidases of approximately 25-30 kDa. These proteins are relatively well conserved
with 61-79% of sequence identity between KLK1-3 and 38-57% for KLK4-15 [114].
Crystallographic structural analysis revealed that all 15 KLKs bear a similar active site
formed by two asymmetric juxtaposed beta-barrels and two alpha-helices, which allows
the catalytic mechanism of KLKs to be highly conserved. On the other hand, their external
surface is more variable, particularly in their specificity sub-sites, exposed charges, and
composition and length of external loops, which yields different regulatory mechanisms
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and substrate specificity for each KLK [115]. Kallikreins are first synthesized as a
homologous single-chain pre-pro-enzyme with a 244-276 amino acid sequence, which can
be divided into three parts: the pre-domain acting as the signal peptide, the pro-domain for
KLK activation and the KLK core domain, which contains residues of the catalytic triad
[78]. The disulfide bonds necessary for correct folding of each KLK are provided by at
least 10 cysteine residues. A pre-signal peptide of 16-33 amino acids dictates the transit of
each newly synthesized KLK to the endoplasmic reticulum and into the Golgi apparatus
for glycosylation. After subsequent cleavage of the signal peptide, each KLK is secreted
into the extracellular space as an inactive pro-form, or zymogen. For activation to occur,
the 3-37 amino acid length pro-domain must be removed by proteolysis. A threedimensional (3D) conformational change of the active site follows this cleavage, allowing
binding of trypsin and/or chymotrypsin substrates and producing the proteolytic activity of
KLKs [82, 88, 114]. Since most KLKs possess trypsin-like endopeptidase activity, an
activation cascade between the different members of the KLK family can occur, which
enables co-regulation of several KLKs [116]. Such proteolytic KLK cascades have been
reported for KLK5, KLK7 and KLK14 in skin desquamation and between KLK2-5 in
semen liquefaction [82].
Tight control over KLK proteolytic activity is essential since pro-KLK activation is
irreversible and the resulting excess proteolytic activity poses a risk for biological
dysfunction and the development of numerous pathoses. Control of KLK activity is thus
provided by strict regulation of the physical and chemical properties of the local
microenvironment. For example, metal ions such as Zn2+ modulate the process of semen
liquefaction by inhibiting KLKs. Once the Zn2+ is complexed by semenogelin, the KLKs
are disinhibited and can carry out their function in this process [117]. Furthermore, KLK
activity is regulated in a pH-sensitive manner, resulting in variable KLK activity in
different skin layers [86]. Endogenous inhibitors (e.g., Kazal and Kunitz type inhibitors)
may also regulate KLK activity through reversible interactions with the KLK active site
[114]. For example, the lymphoepithelial Kazal type-related inhibitor (LEKTI) is involved
in the control of KLK function in the skin [118, 119]. A skin disease, Netherton Syndrome,
is associated with dysregulation of KLK activity by way of mutations in the encoding gene
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for serine peptidase inhibitor, Kazal type 5 (SPINK5) [120]. Finally, members of the serpin
family [e.g., kallistatin, a1-antichymotrypsin, antithrombin III, a1-antitrypsin, a2antiplasmine and protein C inhibitor (PCI)] are also endogenous irreversible KLK
inhibitors [121].

1.3.4

Expression patterns of KLKs in normal physiology and
disease states

One or more KLKs are found in nearly every human tissue and each KLK displays a
restricted individual expression pattern [122]. Under physiological conditions, certain
KLKs are highly expressed in a limited number of tissues, e.g., KLK2 and KLK3 in the
prostate gland, KLK4 in developing teeth, and KLK6 in the brain and central nervous
system [123]. Conversely, the remaining KLKs (KLK1, KLK5, KLK7-15) are expressed
at varying levels in a wide variety of tissues [122]. Biological fluids such as seminal
plasma, breast milk, ovarian follicular fluid, breast cyst fluid, amniotic fluid, cervicovaginal fluid, cerebrospinal fluid and urine also contain KLKs that are secreted by
epithelial/glandular cells. The observed patterns of several KLKs being co-expressed in the
same tissue led to the development of the “KLK activome” concept, which suggests
common mechanisms of regulation [122]. Certain KLK genes have been shown to share
regulatory sequences, like the androgen receptor (AR)-binding motifs found in the KLK2
and KLK3 sequences [108, 124]. Similar regulatory promoter sequences involving the
remaining KLKs have yet to be identified. As with nearly all secreted proteases, KLKs
recognize and cleave proteinaceous ECM substrates (e.g., fibronectin, vitronectin, laminin,
collagens and enamelin) and, in doing so, contribute to the processes of cell migration,
invasion and adhesion. Other KLK substrates that are involved in the regulation of cell
migration and adhesion include desmogleins, desmocollin, E-cadherin and L1-cell
adhesion molecule (L1CAM). Intracellular signaling pathways are modulated by KLKs via
activation and/or inactivation of bradykinin receptor B2 (B2R) and protease-activated
receptors (PAR) 1, 2 and 4 [97, 125]. Numerous intercellular mediators (e.g., growth
factors, chaperone molecules, cytokines and hormones) are also targeted by KLKs, most
notably insulin-like growth factor binding proteins (IGFBPs), growth hormone, growth
hormone-releasing hormones, IL-1b and latent transforming growth factor (TGF)-b
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[126-128]. Kallikreins are key players in physiological processes due to their activation
and inactivation of various proteases but they also contribute to disease.
Most KLKs (i.e., KLK1, KLK5-8, KLK10-11, and KLK13-14) are co-expressed in a
multitude of human tissues, including the stratum corneum and upper stratum granulosum
of normal human epidermis, sebaceous glands, eccrine sweat glands, hair follicles, and
nerves [129-132]. Researchers have determined that the KLKs responsible for much of the
serine-protease activity in normal human skin are KLK5, KLK7, KLK8 and KLK14
[133-135]. These KLKs and other skin-barrier proteins are transported to the stratum
corneum interstices by lamellar granules in keratinocytes. Once they arrive in the stratum
corneum interstitial milieu, they are secreted and can participate in a proteolytic activation
cascade initiated by KLK5. Auto-activated KLK5 activates the downstream pro-enzyme
forms of KLK7, KLK8 and KLK14 by cleaving their pro-peptides. The activated form of
KLK14 may then activate pro-KLK15 in a positive-feedback loop [136]. In order to
maintain healthy skin-barrier function, pro-KLKs are activated and perform three tasks: (i)
regulation of skin renewal and barrier thickness via promotion of desquamation and/or
keratinocyte proliferation [137], (ii) modulation of the lipid-rich permeability barrier
through regulation of lipid-processing enzymes and/or by the activation of keratinocyteexpressed PAR2 [138, 139], and (iii) induction of antimicrobial and innate immune
responses via the processing of antimicrobial peptides and pro-cytokines [140-143]. Skin
desquamation is the most well understood of the above-mentioned processes.
Various diseases of the skin (e.g., atopic dermatitis, psoriasis and acne rosacea) have been
tied to dysregulation of KLKs. The pathogenesis of atopic dermatitis has been linked to
aberrant activity of KLKs, specifically KLK7 [144]. Investigators found that transgenic
mice with KLK7 upregulation in the skin developed increased epidermal thickness and
dermal inflammation, which is consistent with the clinical manifestation of human atopic
dermatitis [145]. Upregulation of PAR2 was also observed in the epidermis of individuals
with atopic dermatitis, which suggested that a KLK-PAR2 mechanism may be linked to
the pathogenesis of this skin disease [146].
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Psoriasis is another skin condition in which KLKs play a key role. This condition affects
nearly 2% of the population and has a multifactorial etiology. Both autoimmune and
epidermal aberrations lead to the characteristic epidermal scaling and hyperkeratosis. The
resulting plaques are well demarcated, oval-shaped, and reddish in color with silvery
scales; adjacent skin is often of normal appearance [147]. To date, the most promising KLK
target for new psoriasis treatments appears to be KLK8. The total trypsin-like activity at
sites of psoriatic lesions is markedly greater than matched normal skin from subjects with
psoriasis and normal skin from healthy subjects [148]. The skin-associated trypsin-like
KLK8 has been found to be upregulated in psoriatic skin lesions compared to control skin
tissues [149] and KLK8 was identified as one of 130 differentially upregulated genes
specifically associated with psoriasis skin lesions [150]. It has thus been demonstrated that
KLK8 mRNA, protein and trypsin-like activity levels are strongly correlated with psoriatic
skin lesions.
There is evidence that KLK8 is also involved in the pathogenesis of schizophrenia and
other mood and anxiety disorders. Investigators have shown that KLK8-mediated
neuregulin-1/human epidermal growth factor receptor-4 activation leads to impairment of
gamma-aminobutyric acid-mediated inhibitory transmission, and this pathway is
associated with disease processes in schizophrenia [151]. A study using KLK8-knockout
mice revealed a loss of neurogenesis and synaptogenesis in the hippocampus [152]. A
separate research group found that KLK8-knockout mice were unable to regulate
physiological synaptic plasticity and suffered from long-term potentiation deficits and frail
memory acquisition [153]. In another study, KLK8 activity induced EPHB2 receptor
activation, which triggered a cascade of events that resulted in enhanced transcription of
FKBP5 and lead to anxiety-like behavior in mice [154].
Another KLK associated with diseases of the central nervous system is KLK6, which has
been linked to multiple sclerosis, Lewy body diseases and CNS inflammation. In one
report, mice lacking KLK6 were shown to have fewer mature oligodendrocytes and
myelin-associated proteins in their spinal cords than wild-type mice [155]. Another report
revealed that adenoviral delivery of KLK6 reduced the burden of toxic a-synuclein in
mouse models of Lewy body dementia [156]. Finally, researchers demonstrated that
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administration of KLK6-neutralizing antibodies in a mouse model of autoimmune
encephalomyelitis reduced the severity of clinically relevant deficits [157].
The roles of KLKs as regulators of skin immunity have been highlighted in studies of the
pathobiology of acne rosacea [158-161]. Individuals with rosacea have a dysfunctional
skin barrier, which leads to facial inflammation in response to internal and external stimuli
(e.g., sun exposure, alcohol consumption, spicy food, hot beverages, high temperatures and
emotional stress). These individuals also have an exacerbated response to skin irritants and
allergens [162]. Investigation of the facial skin in subjects with rosacea lesions revealed
KLK5 overexpression, elevated KLK-mediated serine-protease activity and enhanced
proteolysis of the cathelicidin antimicrobial peptide LL-37 [163]. In an animal model,
subcutaneous injection of active KLK5 in amounts equal to those observed in human
rosaceatic skin lesions was found to increase cathelicidin processing and induce leukocyte
infiltration and inflammation. These findings appear to confirm the pathogenic
involvement of KLK5 in rosacea [158]. Other studies have implicated KLK7, KLK8 and
KLK14 in the pathogenesis of this disease [134, 135, 164].
In addition to acne rosacea, KLK5 has been shown to play a role in the pathogenesis of
Netherton syndrome, which is a severe, autosomal recessive form of ichthyosis¾a group
of conditions characterized by dry, thickened and scaly skin. Investigators observed that
transgenic mice that expressed human KLK5 (Tg-KLK5) had severe scaling, detachment
of the stratum corneum, skin inflammation and flawed barrier function [165]. Another
group of researchers showed that KLK5 upregulation induced corneodesmosome
degradation but did not alter terminal differentiation marker expression or induce lipid
abnormalities [166].
Multiple KLKs are co-expressed in the prostate gland to varying degrees, including
KLK2-5, KLK11-12, and KLK14-15. While KLK14 is expressed at low levels
(approximately 5 µg/L), KLK3 (also known as PSA) is expressed in significantly greater
amounts (approximately 10 g/L) [82]. Kallikrein-related peptidase-3 was dubbed as PSA
since its production is restricted to prostatic tissues. The normal function of KLK3 in a
healthy prostate gland is to cleave fibronectin and the seminal-gel-forming proteins
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semenogelin 1 and semenogelin 2, which leads to semen liquefaction and enhanced sperm
motility [167-171]. Both KLK5 and KLK14 have been shown to perform in vitro cleavage
of fibronectin and semenogelins and these KLKs are postulated to regulate KLK3 activity
via a zymogen activation cascade; however, KLK3 is the key enzyme responsible for in
vivo semenogelin hydrolysis during seminal clot liquefaction [82]. In prostate tissues, high
Zn2+ concentrations are necessary for the regulation of KLK activity through a reversible
allosteric binding mechanism. Once the ejaculate has been released, Zn2+ ions are
transferred from KLKs to semenogelins, which disinhibits KLKs and allows them to
liquefy the seminal clot [172].
The downregulation of Zn2+ ion transporters in prostate cancer reduces prostatic Zn2+
concentrations and thus leads to enhanced KLK3 activity. This increased enzymatic
activity results in over-degradation of ECM components such as fibronectin, laminin,
galectin 3 and nidogen 1. Furthermore, proteins such as insulin-like growth factor (IGF)binding proteins (i.e., IGFBP3 and IGFBP5) and parathyroid-hormone-related protein
(PTHRP) undergo degradation to a greater degree [173, 174]. Studies have linked KLK3
activity to prostate cancer progression and bony metastases [175]. These findings have
garnered much interest in the development of KLK3-based immunotherapies for the
treatment of advanced prostate cancer [176].
Among the KLKs found in prostate tissues, KLK4 has been identified as an androgenregulated enzyme, which is considerably upregulated in prostate cancer. This has resulted
in efforts to target KLK4 for prostate cancer therapy. Mechanistically, KLK4 initiates
epithelial-mesenchymal transition through a PAR-dependent pathway [177-179]; it also
mediates the process of prostate cancer metastasis to bones [180] and regulates signaling
pathways in prostate cancer progression [181]. One study investigated the delivery of
nanoliposomes containing KLK4-targeting small interfering RNA (siRNA) to mice bearing
prostate cancer tumors and the results showed a marked reduction in tumor growth [181].
Moreover, variations in the KLK4 locus have been associated with prostate cancer
predisposition [182]. These findings have placed KLK4 alongside KLK3 as a potential
target for prostate cancer therapeutics.
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Kallikrein-related peptidase-4 has also been associated with diseases of the oral cavity. A
study using KLK4-knockout mice found improper maturation of tooth enamel crystals as
observed in subjects with amelogenesis imperfecta [183]. Another study supported these
findings by showing that mice lacking both KLK4 and MMP20 could not complete the last
maturation stages of enamel formation [184]. Another group of investigators revealed that
mutations in KLK4 caused autosomal recessive hypomaturation amelogenesis imperfecta
[185]. These investigations further highlight the broad range of organ systems affected by
KLK-associated disease processes.

1.3.5

KLKs in salivary gland tumors

Human tissue kallikreins are upregulated in ovarian, breast and prostate carcinomas, which
has prompted numerous investigations aiming to identify KLK expression profiles in other
disease states, including salivary gland tumors [186-188]. Researchers have studied the
use of KLKs for cancer diagnosis and monitoring, which would have clinical applications
in the management of salivary gland carcinomas [189-191]. Salivary gland tumors
comprise 0.5% of all malignancies and 2% to 5% of all head and neck malignancies
worldwide [192-194]. Due to the relatively low incidence rates of salivary gland tumors,
it is possible that the impact of these neoplasms is misrepresented. To date, the upregulation
of KLKs in malignant tumors has been associated with both favorable and poor prognoses
[195]. The potential for certain members of the KLK family to guide differential diagnoses,
subtyping and monitoring of patients with salivary gland tumors has been a driving force
for research in this field.
Both KLK3 and KLK5 have been identified in normal and diseased salivary gland tissues
[188, 196, 197]. A recent study analyzed normal salivary gland tissues (NSGTs) and a
variety of salivary gland tumors¾both benign and malignant¾for expression of KLK3
and KLK5 proteins. Tumors included PA, AdCC, PLGA, ACC, MEC and adenocarcinoma
not otherwise specified (ANOS) affecting both minor and major salivary glands [197]. The
results indicated no significant differences in KLK5 levels in most salivary gland tumors.
Immunostaining for KLK5 protein was most prominent in the keratinizing epithelium of
PA, whereas KLK3 was not detected in the salivary gland tumors investigated.
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Kallikrein-related peptidase-6, which is also known as a zyme/protease M/neurosin, is
found in a variety of glandular and non-glandular tissues, such as salivary gland, brain,
heart, liver, kidney, breast, trachea, spleen, thymus, prostate, testis, uterus and placenta
[198-201]. One study found significantly reduced levels of KLK6 in metastatic breast
carcinoma cells in comparison to primary carcinoma cells or normal breast epithelial cells
[190, 198]. In salivary gland tumors¾both benign and malignant¾and control tissues,
KLK6 has been localized using an immunostaining method [202]. The tumors studied
included PA, AdCC, PLGA, ACC, MEC and ANOS. Investigators used an
immunoreactivity scoring system to grade the staining in ductal and non-ductal cells in the
tumors. For all tumors except PA of minor salivary gland origin, overall staining for KLK6
was greater in non-ductal cells. Overall, there was a decreased expression profile for KLK6
in salivary gland tumors but no tumor-specific patterns were observed.
A more limited variety of tumors were subjected to immunostaining analysis to determine
the expression profile of KLK7 [203]. Specifically, ductal and non-ductal cells in PA,
AdCC and MEC were scored and compared with NSGTs. Immunoreactivity scores for PA
and AdCC were higher than those for MEC, which suggested a possible role for KLK7 in
tumors of myoepithelial differentiation. Since KLK7 is often co-expressed with other
KLKs but lacks specificity to any single type of salivary gland tumor, it was theorized that
KLK7 participates in an enzymatic cascade in the tumorigenesis of myoepithelial cells.
Before such pathways can be elucidated, correlation of immunostaining analyses to
quantitative measurements of KLK7 mRNA will be required.
A variety of healthy tissues express KLK8, including esophagus, skin, testis, tonsil, kidney,
breast and salivary gland. This protein is also found in bodily fluids, such as breast milk,
amniotic fluid, seminal fluid and serum [204]. Kallikrein-related peptidase-8 has not been
linked to many cancers, but some evidence suggests that it may serve as a biomarker and
prognostic indicator in ovarian cancer [205]. A group of investigators recently studied the
expression profiles of KLK8 in salivary gland tumors¾both benign and malignant¾and
control tissues [206]. Immunostaining analyses of PA, AdCC, PLGA, ACC, MEC and
ANOS of both minor and major salivary glands revealed that KLK8 was found at relatively
higher levels in ductal cells and non-ductal cells of most salivary gland tumors. In general,
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KLK8 staining scores were significantly higher in ductal cells than in non-ductal cells, and
malignant tumors expressed higher levels of KLK8 than both benign tumors and NSGT
controls.
Kallikrein-related peptidase-10 has been studied in both normal tissues and various
malignancies. Most notably, KLK10 was reported to be strongly expressed in the
pancreatic islets of Langerhans and it may regulate the pro-hormone activation of insulin,
glucagon, somatostatin and pancreatic polypeptide [172, 207, 208]. High levels of KLK10
have been noted in colon cancer cells [209], and linked to testicular, breast and colorectal
cancer [210-212]. It is believed that vitamin D3 in normal keratinocytes regulates KLK10
expression, and it has been implicated with KLK6 in skin carcinogenesis [213]. A separate
study found that KLK10 and KLK6 co-expression was associated with poorer prognosis in
pancreatic ductal carcinoma [214]. Investigators have also shown the expression of KLK10
in salivary gland tumors and control tissues [215]. Using immunostaining techniques,
researchers analyzed the immunoreactivity profile of KLK10 in NSGTs, PA, AdCC and
MEC. Pleomorphic adenoma showed significantly lower KLK10 levels than control
tissues. Neither AdCC nor MEC demonstrated significant alteration in KLK10 levels.
Relative to MEC, PA had significantly reduced levels of KLK10, which provided further
evidence for aberrant KLK expression in the tumorigenesis of myoepithelial cells [215].
Many reports have linked upregulation of KLKs with poorer patient prognoses, but several
studies have found that KLK up- or downregulation may be a favorable prognostic
indicator. Kallikrein-related peptidases promote or inhibit cancer cell growth,
angiogenesis, invasion and metastasis through proteolysis of growth-factor binding
proteins [195, 208, 216]. Moreover, KLKs trigger the activation of growth factors and other
proteases, the release of angiogenic or antiangiogenic factors, and the degradation of ECM
components [195, 208, 216]. One research group investigated the expression levels of
KLK14 in salivary gland tumors¾both benign and malignant¾and control tissues [217].
Levels of KLK14 were then correlated with clinical parameters including tumor stage,
tumor grade, and the outcome of disease to elucidate associations between KLK14 levels
and clinical parameters useful for prognostication. Three salivary glands tumors were
studied: PA, AdCC and MEC. All tumor samples and control tissues demonstrated strong
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expression of KLK14 in ductal and non-ductal cells. Both PA and AdCC revealed higher
KLK14 staining scores than normal glands and MEC samples; however, there were no
statistically significant associations between levels of KLK14 and the clinical parameters
studied. These investigators concluded that analysis of KLK14 protein expression in PA,
AdCC and MEC may not by itself be useful for determining prognosis; however, the
dysregulation of KLK14 in these tumors may be involved in an unrecognized enzymatic
cascade involving multiple KLKs.
Neoplasms of the major and minor salivary glands present diagnostic and management
challenges due to their overlapping patterns and discrepancies between histopathological
classifications and prognostic determinants [218]. Preliminary studies have identified
variable expression patterns for KLK 3, KLK5-8, KLK10, and KLK13-14, but these
reports have looked at the post-transcriptional level (i.e., the protein level) [197, 202, 203,
206, 215, 217]. To utilize KLKs as biomarkers for diagnosis and prognosis, discernable
patterns for KLK expression in salivary gland tumors (e.g., PA, AdCC, PLGA, ACC, MEC
and ANOS) must first be identified. It has also been postulated that quantitation of tumorspecific KLK mRNA and the corresponding KLK proteins may shed light on the currently
limited understanding of enzymatic cascades involved in salivary gland tumorigenesis
[122, 172].
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Chapter 2

2

Hypotheses and rationale

2.1 Hypotheses
Hypothesis 1: We hypothesize that the expression of KLK mRNA in PA will be
dysregulated relative to NSGT controls.
Hypothesis 2: We hypothesize that dysregulated expression will also be observed at the
post-transcriptional level as assessed by immunostaining techniques.
Hypothesis 3: For PAs showing histologic evidence of capsular violation (i.e., invasion
and/or perforation), we hypothesize that KLK mRNA and protein levels will not be
different from control tissues.
Hypothesis 4: We hypothesize that tumor size will not be associated with capsular
violation.

2.2 Rationale
Kallikrein-related peptidase genes are co-expressed in various human tissues and are
frequently dysregulated in disease states, which suggest the existence of a regulatory role
for KLK genes or proteins in disease pathogenesis [172, 195, 209, 219, 220]. Well
established proteolytic cascades have been documented for both normal and
pathobiological processes, such as semen liquefaction, skin desquamation, innate
immunity and degradation and remodeling of ECM [221]. Applied understanding of KLKs
in disease processes is best typified by KLK3 (PSA), which serves as a valuable biomarker
for the screening, diagnosis, staging and monitoring of prostate cancer [172, 195, 209].
Many KLKs are expressed in predictably altered proportions in malignant tumors, which
has prompted researchers to develop novel applications for cancer screening, diagnosis,
prognosis, management, and monitoring [172, 221].
Research groups have analyzed a variety of salivary gland neoplasms¾PA, AdCC, ACC,
PLGA, MEC and ANOS¾to determine the relative proportions of KLK proteins expressed
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compared to NSGT controls [202, 203, 206, 215, 222, 223, 217, 197]. The determination
of a KLK mRNA and protein profile for PA may help to establish a causative link between
KLK dysregulation and the pathophysiology of this tumor. In doing so, we hope to further
our understanding of the roles of KLKs in tumorigenesis, and perhaps facilitate the
development of clinically relevant applications for KLKs in the diagnosis, prognosis and
postoperative monitoring of this salivary gland neoplasm. Ultimately, the development of
a simple and convenient serum or saliva test may benefit patients living in remote
communities with limited access to surgeons for biopsy or surgical follow-up.

2.3 Objectives
Objective 1: To quantitate and compare the expression levels of KLK1-15 mRNA in PA
specimens and NSGT controls using quantitative real-time reverse transcription
polymerase chain reaction (RT-qPCR).
Objective 2: To analyze protein expression for dysregulated KLKs (determined in
Objective 1) via immunostaining techniques.
Objective 3: To identify associations between histologic evidence of capsular violation
(i.e., invasion and/or perforation) and the expression of KLK mRNA and proteins in PA
specimens.
Objective 4: To identify associations between histologic evidence of capsular violation and
PA tumor size.
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Chapter 3

3

Materials and methods

3.1 Tissue specimens
3.1.1

Ethics approval

Approval for this case-control study was granted by the University of Western Ontario
Health Sciences Research Ethics Board (HSREB) for research involving human subjects,
which follows the Tri-Council policy statement: Ethical Conduct of Research Involving
Humans, and the Health Canada/International Council for Harmonization Good Clinical
Practice Guidelines. Under the applicable laws and regulations of Ontario, the HSREB has
reviewed and granted approval for this study (Approval number: 103783). The membership
of this Research Ethics Board (REB) also complies with the membership requirements for
REBs as defined in Division 5 of the Food and Drug Regulations.

3.1.2

Specimen number and tissue handling

Tissue specimens were obtained from twenty-six (n = 26) subjects who underwent surgical
treatment for PA between November 13th, 2007, and December 15th, 2008, at the
Department of Otolaryngology−Head & Neck Surgery, London Health Sciences Centre,
London, Ontario, Canada (see Table 3.1). Diagnosis of the lesion was based on the World
Health Organization classification of tumors [224]. Each subject served as his/her own
control as NSGT lying outside the tumor capsule was also harvested from each site. After
surgical resection, both the PA specimens and control tissues were immediately snapfrozen in liquid nitrogen for storage in a freezer cooled to -80o C.

3.1.3

Demographics and selection criteria

Selection criteria included: (i) confirmation of diagnosis (PA or NSGT) by histologic
examination, and (ii) the availability of sufficient tissues for RNA extraction. Patient ages
ranged from 19 to 84 with a mean of 48, and the female-to-male ratio was 17:9. Tumors
were predominantly in the parotid gland (21 subjects), with five samples taken from the
submandibular gland (5 subjects).
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It should be noted that only 17 of the original 26 samples provided sufficient RNA yield
for subsequent analyses. The modified age range for selected cases was 20 to 84 with a
mean of 53, and the female-to-male ratio was 11:6. Sixteen tumors were in the parotid
gland (16 subjects) and 1 tumor was in the submandibular gland (1 subject).
Table 3.1: Demographic information for paired PA and NSGT specimens
Case

Age (years)

Gender

Salivary gland

1*

23

F

Submandibular

2

46

M

Parotid

3

58

M

Parotid

4

20

F

Parotid

5

61

F

Parotid

6

45

M

Submandibular

7

39

F

Parotid

8

84

F

Parotid

9

73

M

Parotid

10

65

F

Parotid

11

36

M

Parotid

12

42

F

Parotid

13

40

F

Parotid

14*

19

M

Submandibular

15

66

F

Parotid

33

16

70

F

Parotid

17

43

M

Parotid

18

52

F

Parotid

19

67

F

Parotid

20*

78

M

Parotid

21*

54

F

Parotid

22*

24

M

Parotid

23*

39

F

Submandibular

24*

38

F

Parotid

25*

23

F

Submandibular

26*

42

F

Parotid

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; M,
male; F, female. *Insufficient RNA yield for subsequent analyses.

3.2 KLK mRNA analysis
3.2.1

RNA isolation

Specimens were retrieved from the freezer and allowed to warm to room temperature. All
steps were performed at room temperature (20-25o C) unless otherwise noted. A 100 mg
piece of tissue was added to a 1.5 mL sterile centrifuge tube and combined with 1 mL of
TRIzolÔ Reagent (Thermo Fisher Scientific, Carlsbad, CA, USA, Catalog number:
15596026) for RNA isolation. It should be noted that proper microbiological aseptic
technique was employed when working with all samples. The solution was homogenized
using a homogenizer. The lysate was centrifuged (12,000 x g) for 5 minutes at 4-10o C,
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then the supernatant was transferred to a new tube. The solution was incubated for 5
minutes to permit complete dissociation of the nucleoproteins complex. Next, 0.2 mL of
chloroform was added to the tube and the tube cap was closed. This solution was incubated
for 2-3 minutes. The sample was then centrifuged (12,000 x g) for 15 minutes at 4o C. The
mixture separated into three layers: a lower red phenol-chloroform phase, an interphase,
and a colorless upper aqueous phase. The upper aqueous phase containing the RNA was
transferred to a new tube using a pipette. A solution of 70% ethanol was combined in a
centrifuge tube with the RNA solution in a 1:1 ratio (400 µL of each solution was used).
The mixture was then hand-mixed.
The Aurumä Total RNA mini kit (Bio-Rad Laboratories, Hercules, CA, USA, Catalog
number: 7326820) was next assembled. An RNA binding column was inserted into a 2 mL
capless wash tube. The homogenized lysate solution was pipetted onto the RNA binding
column. This was centrifuged for 60 seconds. The RNA binding column was then removed
from the wash tube, the filtrate from the wash tube was discarded, and the column was
replaced into the same wash tube. The low stringency wash solution was provided as a 5x
concentrate. Four volumes (80 mL total) of 95-100% ethanol were added to the low
stringency wash solution before initial use. A 700 µL volume of low stringency wash
solution was added to the RNA binding column and the mixture was centrifuged for 30
seconds. The low stringency wash solution was discarded from the wash tube and the
column was replaced into the same wash tube. A 700 µL volume of high stringency wash
solution was added to the RNA binding column. This was then centrifuged for 30 seconds.
The high stringency wash solution was discarded from the wash tube and the column was
replaced into the same wash tube. A 700 µL volume of low stringency wash solution was
again added to the RNA binding column then centrifuged for 30 seconds. The low
stringency wash solution was discarded from the wash tube and the column was replaced
into the same wash tube. The solution was centrifuged for an additional 2 minutes to
remove residual wash solution. The RNA binding column was then transferred to a 1.5 mL
capped microcentrifuge tube. A volume of 80 µL of the elution solution was pipetted onto
the membrane stack of the RNA binding column and the solution was left to saturate the
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membranes for 1 minute. The tube was then centrifuged for 2 minutes to elute the total
RNA. The eluted RNA samples were used immediately.
The Qubitä RNA BR Assay Kit (Thermo Fisher Scientific, Carlsbad, CA, USA, Catalog
number: Q10210) was utilized to measure RNA quantity. The required number of 0.5 mL
tubes were set-up along with 2 standards. It should be noted that only thin-walled, clear
0.5 mL PCR tubes were used, such as those recommended by the manufacturer. The tube
lids were labelled. The Qubitâ working solution was prepared by diluting the Qubitâ RNA
BR Reagent to 1:200 in Qubitâ RNA BR Buffer. A clear plastic tube was used each time
the Qubitâ working solution was prepared. A calculated amount of Qubitâ working
solution was prepared for distribution to all standards and samples. To each of the tubes
used for standards was added 190 µL of Qubitâ working solution. A 10 µL volume of
Qubitâ standard was then added to the appropriate tubes and mixed by vortexing for 2-3
seconds. Care was taken not to create bubbles. It should be noted the final working volume
in each tube was exactly 200 µL. For the next step, Qubitâ working solution was added to
individual assay tubes so that the final volume in each tube after adding sample was 200
µL. Note: Samples were anywhere from 1-20 µL; a corresponding volume of Qubitâ
working solution (anywhere from 180-199 µL) was added to each assay tube. After each
sample was added to the assay tubes containing the correct volumes of Qubitâ working
solution, the mixture was vortexed for 2-3 seconds. All tubes were incubated at room
temperature for 2 minutes.
On the Home screen of the Qubitâ 2.0 Fluorometer, the ‘RNA Broad Range’ assay type
was selected. A new calibration was performed as follows: A sample tube was inserted into
the sample chamber, the lid was closed, then ‘Read’ was selected. Once the reading was
completed (~3 seconds), the sample tube was removed. The instrument displayed the
results on the sample screen.
The value displayed corresponded to the diluted assay concentration (in µg/mL). To find
the concentration of the original sample, a calculation was performed using the following
equation:
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RNA concentration of sample = QF value • (

"##
$

)

where QF value = the value given by the Qubitâ 2.0 Fluorometer,
x = the number of µL of sample added to the assay tube
This equation generated a result with the same units as the value given by the Qubitâ 2.0
Fluorometer (i.e., µL/mL). The same process was repeated until RNA concentrations were
obtained for all samples. Samples with insufficient RNA yield for detection by the Qubitâ
2.0 Fluorometer did not meet the selection criteria for this study (see Section 3.1.3).

3.2.2

Complementary DNA synthesis

The isolated RNA was next transcribed into complementary DNA (cDNA) by reverse
transcription using the iScriptä cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA,
USA, Catalog number: 1708890). A volume of 405 µL of nuclease-free water, 180 µL of
5x iScriptä Reaction Mix and 45 µL of iScriptä Reverse Transcriptase were combined in
a 1.5 mL collection tube. A volume of 16 µL of the mixed reagents was then combined
with 4 µL of RNA solution, which had been previously isolated from a PA or NSGT
specimen. The reaction was completed in a T100 thermal cylinder (Bio-Rad Laboratories,
Hercules, CA, USA). The priming process was carried out for 5 minutes at 25o C followed
by reverse transcription for 20 minutes at 46o C, then reverse transcription inactivation for
1 minute at 95o C. This process was performed for each sample.

3.2.3

Quantitative real-time reverse transcription PCR

The next step involved RT-qPCR reactions using the CFX Connect Real-Time PCR
Detection System (Bio-Rad Laboratories, Hercules, CA, USA). Each custom PCR plate
accommodated six specimens and came loaded with KLK and b-actin primer assays from
Qiagen (see Table 3.2). Polymerase chain reaction mixtures consisted of the following: 10
µL of SsoFastä EvaGreenâ Supermix (Bio-Rad Laboratories, Hercules, CA, USA,
Catalog number: 1725201), 2 µL of primer assay (KLK + b-actin), 1 µL of previously
synthesized KLK cDNA, and 7 µL of nuclease-free water. It should be noted that the
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SsoFastä EvaGreenâ Supermix contained dNTPs, magnesium chloride, Sso7d-fusion
polymerase, EvaGreen dye and stabilizers. A 20 µL volume of the reaction mixture was
transferred by pipette to the appropriate well on a PCR plate. The RT-qPCR protocol
involved one cycle of 10 minutes at 95o C for enzyme activation, followed by 40 cycles of
15 seconds at 95o C for denaturation and 40 cycles of 1 minute at 60o C for
annealing/extension.
Table 3.2: Qiagen primer assays for RT-qPCR
Primer assay

Catalog number

b-actin

QT01680476

KLK1

QT00020664

KLK2

QT00088466

KLK3

QT00027713

KLK4

QT00495159

KLK5

QT00010437

KLK6

QT00013972

KLK7

QT00028343

KLK8

QT00017689

KLK9

QT00057190

KLK10

QT00039816

KLK11

QT00011011

KLK12

QT00067977
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KLK13

QT00029876

KLK14

QT00039928

KLK15

QT00035735

Abbreviations: KLK, kallikrein; RT-qPCR, quantitative real-time reverse
transcription polymerase chain reaction.

3.2.4

Melting curve analysis of PCR products

The specificity of each PCR amplification was verified by post-RT-qPCR melting curve
analysis. The sequence started at 65o C for 5 seconds and increased by 0.5o C increments
up to 95o C, holding for 5 seconds at each new temperature point. Comparison of generated
melting point temperatures (Tm) were made to known Tm values for KLK1-15 and b-actin
as provided by the manufacturer (see Table 3.3). When generated Tm values differed from
known values, or melting curves demonstrated dimer formation for the primers, the data
point was excluded or interpreted as showing no KLK expression.
Table 3.3: Melting point values for primers
Primer

Tm value (± 0.5o C)

b-actin

85.5

KLK1

82.5

KLK2

82.5

KLK3

84.5

KLK4

83.5

KLK5

79.5

KLK6

81.5
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KLK7

84.5

KLK8

82.5

KLK9

85.5

KLK10

82.0

KLK11

80.5

KLK12

81.0

KLK13

85.0

KLK14

85.0

KLK15

84.0

Abbreviations: KLK, kallikrein; RT-qPCR, quantitative real-time reverse
transcription polymerase chain reaction; Tm, melting point temperature.

3.2.5

Statistical analysis

Relative quantitation of RT-qPCR data was performed using the comparative CT (DDCT)
method. The threshold cycle (CT) of each KLK (i.e., KLK1-15) in PA or control specimens
was normalized to the corresponding CT of the housekeeping gene, b-actin, to yield a DCT
value. Subsequent calculations for mean DCT, standard deviation, DDCT, mean DDCT, and
standard error of the mean [SEM] values were performed using GraphPad Prism, Version
7.0c for Mac OS X (GraphPad Software, CA, USA). The level of significance was set at P
< .05.
The following formula was used in the calculation of mean DDCT values:
Mean DDCT = 2-[CT(KLK) – CT(b-actin)]
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For each KLK, a reference value of 1 was set for the mean DDCT value of the NSGT
specimens; for the PA specimens, the KLK-specific mean DDCT value was calibrated
accordingly. Overall, the calculated relative quantities for KLK1-15 in PAs and NSGTs
were compared. It should be noted that mean DDCT and SEM values were used for plotting
Figs. 4.1-4.15 but individual DCT values (not shown) for each PA and NSGT specimen
were used for the Wilcoxon signed-rank test calculations. The asterisks denoting statistical
significance (P < .05) in Figs. 4.1, 4.12 and 4.13 are thus based on the individual data
points (DCT).

3.3 Immunohistochemistry
3.3.1

Sample selection and preparation

Each of the 26 PA specimens and matched NSGTs were fixed in formalin and embedded
in paraffin according to well established techniques [225]. Using a microtome (Microm
HM 325, GMI Inc., MN, USA, SKU number: 8243301006), 5 µm thick serial sections
were prepared from the tissue blocks. These sections were transferred to a water bath at
45o C then mounted onto positively charged microscope slides for incubation at 37o C
overnight.

3.3.2

KLK antibody selection

The antibodies used in this study were chosen based on the results of our RT-qPCR
analyses. For PA specimens having KLK DCT values that were significantly greater or
lesser than the values for matched control tissues, the corresponding KLK antibodies were
purchased (see Table 3.4). Our investigations revealed dysregulation of KLK1, KLK12 and
KLK13 in PA specimens (see Section 4.1). While the DCT value for KLK8 in all PA samples
was not significantly different from DCT value for control tissues, the KLK8 antibody was
purchased to be used as a reference in the immunostaining experiments.
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Table 3.4: KLK-specific antibodies
KLK

Antibody

Supplier

Catalog number

KLK1

Rabbit

Bioss

BS-1963R

Novus Biologicals

NB200-137

Abcam

AB113227

Abgent

genta-AP6327B

(polyclonal)
KLK12

Rabbit
(polyclonal)

KLK13

Rabbit
(polyclonal)

KLK8

Rabbit
(polyclonal)

Abbreviations: KLK, kallikrein.

3.3.3

Immunostaining procedure

Evaluation of KLK1, KLK12, KLK13 and KLK8 expression in PA and matched NSGT
specimens was performed using standard immunostaining techniques. Confirmation of
immunostaining specificity was achieved by running preliminary experiments with
negative and positive control tissues. Positive control tissues (i.e., skin or prostate gland)
known to express each respective KLK were used to demonstrate a positive staining
reaction and to guide preparation of KLK antibody titers (see Table 3.5) [122, 136, 172,
187, 189, 208, 221, 222]. It should be noted that the negative and positive controls were
batch controls, not on-slide controls.
To prepare the slides for immunostaining, they were first deparaffinized then hydrated
through xylenes and a graded ethanol series according to the following protocol:
The slides were soaked for 5 minutes each in 3 consecutive xylenes baths. Slides were
then soaked in 100% ethanol for 3 minutes. Slides were transferred into 95% ethanol
for 3 minutes followed by a soak in 70% ethanol for 1 minute. Slides were then soaked
in 100% distilled water for 3 minutes. Quenching in a solution of 3% hydrogen
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peroxide in methanol was performed for 5 minutes followed by a rinse with 100%
distilled water. Finally, the slides were bathed in phosphate-buffered saline (PBS) on
an agitator device.
The following protocol was followed for the KLK1, KLK12, KLK13 and KLK8
experiments:
Antigen retrieval was performed using citrate buffer (at pH 6.0) in a decloaking
chamber at 125o C for the KLK12 and KLK13 antigens; for the KLK1 and KLK8
antigens, EDTA buffer (at pH 9.0) was used. After antigen retrieval, slides were rinsed
and blocked using 10% horse serum. Incubation with the KLK-specific primary
antibody was performed using the appropriate dilution, temperature and time frame
(see Table 3.5). After allowing antibodies to bind antigens overnight, excess antibody
was removed by rinsing with PBS. Slides were then treated with the secondary antibody
(ImmPRESS™ HRP Anti-Rabbit IgG [Peroxidase] Polymer Detection Kit, Vector
Laboratories, CA, USA, Catalog number: MP-7401) and incubated at room
temperature for 30 minutes. Slides were then rinsed with PBS. A 3,3’diaminobenzidine (DAB) solution (Vector Laboratories, CA, USA, Catalog number:
SK-4100) was applied to the slides for 6-8 minutes. Deactivation of the DAB solution
was achieved by rinsing the slides with water for 5 minutes. Counterstaining was
performed with haematoxylin. Dehydration was achieved by transferring slides through
a graded ethanol series followed by a soak in xylenes. Coverslips were applied to the
slides using Cytosealä Mounting Medium (VWR, Toronto, Canada, Catalog number:
48212154).
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Table 3.5: Antibody titers and incubation protocols for immunostaining
experiments
KLK

Antibody titer

Positive control

Incubation

(µL antibody/µL

tissue

protocol

horse serum)
KLK1

1/1000

Prostate gland

Overnight at 4o C

KLK12

1/100

Skin

Overnight at 4o C

KLK13

1/2000

Skin

Overnight at 4o C

KLK8

1/200

Skin

Overnight at 4o C

Abbreviations: KLK, kallikrein.

3.3.4

Staining immunoreactivity scores

A semi-quantitative analysis of the immunostained slides was performed under light
microscopy according to previously described techniques [223, 217]. Staining was
evaluated by both a senior Oral & Maxillofacial Pathologist and the graduate student
author. Staining immunoreactivity scores were assigned using the scoring system outlined
in Tables 3.6 and 3.7. For each slide, both the proportion (Prop, 0-5) and the intensity (Int,
0-3) of cell staining were scored, and an overall staining score (OSS, ranging from 0-8)
was assigned based on the sum of the P and I values. An OSS of 0 represented a negative
score, and an OSS from 2-8 represented a positive score.
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Table 3.6: Staining intensity scoring system
Score

Staining intensity

0

None

1

Weak

2

Moderate

3

Strong

Table 3.7: Staining proportion scoring system

3.3.5

Score

Staining proportion (%)

0

0

1

<1

2

1-10

3

10-33

4

33-66

5

> 66

Statistical analysis

Statistical calculations were performed using GraphPad Prism, Version 7.0c for Mac OS
X (GraphPad Software, CA, USA). The level of significance was set at P < .05.
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3.4 Analysis of tumor characteristics
3.4.1

Capsular invasion and/or perforation

The original histology slides used for diagnosing PA in cases 1-26 were analyzed for
evidence of capsular invasion and/or perforation. Capsular invasion was defined as
penetration of PA tumor cells into¾but not completely through¾the fibrous tumor
capsule. Capsular perforation was defined as penetration of PA tumor cells completely
through the fibrous tumor capsule into the surrounding normal tissues.

3.4.2

Tumor size

Measurements of unprocessed tumor specimens (in cm3) were obtained from the original
surgical pathology reports.

3.4.3

Statistical analysis

Statistical analysis was performed to determine associations between capsular violation
(i.e., invasion and/or perforation) and KLK mRNA and/or proteins. Calculations were
carried out using GraphPad Prism, Version 7.0c for Mac OS X (GraphPad Software, CA,
USA). The level of significance was set at P < .05.
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Chapter 4

4

Results

4.1 RT-qPCR analysis
4.1.1

Experimental results

The Qubitâ 2.0 Fluorometer values and the corresponding calculated RNA concentrations
for PA samples and matched NSGT controls are shown in Table 4.1.
Table 4.1: Fluorescence studies and RNA calculations for tissue samples
QF value

RNA (µg/mL)

PA

n/a

n/a

NSGT

n/a

n/a

PA

2.73

136.50

NSGT

2.97

148.50

PA

1.61

80.50

NSGT

0.10

4.80

PA

2.61

130.50

NSGT

0.42

21.05

PA

0.08

3.75

NSGT

3.20

160.00

PA

3.36

168.00

NSGT

3.26

163.00

Case
1*

2

3

4

5

6
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7

8

9

10

11

12

13

14*

15

16

PA

0.10

4.75

NSGT

1.04

52.00

PA

0.79

39.45

NSGT

2.51

125.50

PA

1.11

55.50

NSGT

2.76

110.4

PA

2.58

129.00

NSGT

1.59

106.00

PA

0.50

24.90

NSGT

3.96

198.00

PA

1.25

62.50

NSGT

0.90

44.95

PA

0.20

10.10

NSGT

0.24

11.75

PA

n/a

n/a

NSGT

n/a

n/a

PA

3.08

154.00

NSGT

0.36

18.00

PA

3.99

199.50
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17

18

19

20*

21*

22*

23*

24*

25*

NSGT

4.03

134.30

PA

4.26

121.70

NSGT

1.26

126.00

PA

5.80

145.00

NSGT

5.80

116.00

PA

4.22

168.80

NSGT

3.87

129.00

PA

n/a

n/a

NSGT

n/a

n/a

PA

n/a

n/a

NSGT

n/a

n/a

PA

n/a

n/a

NSGT

n/a

n/a

PA

n/a

n/a

NSGT

n/a

n/a

PA

n/a

n/a

NSGT

n/a

n/a

PA

n/a

n/a

NSGT

n/a

n/a

49

26*

PA

n/a

n/a

NSGT

n/a

n/a

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue;
QF, Qubitâ 2.0 Fluorometer; RNA, ribonucleic acid. *Insufficient RNA yield for
measurement.

4.1.2

Statistical analysis

From the original 26 paired PA and NSGT specimens, only 17 pairs produced sufficient
RNA yield for cDNA synthesis and subsequent RT-qPCR analyses. All 17 pairs of samples
were analyzed and the corresponding DCT values (not shown) for each KLK were recorded.
Mean DDCT (and SEM) values were calculated for each KLK as shown in Table 4.2. We
elected to use DDCt to graphically illustrate the results; however, the paired DCT values
were subjected to Wilcoxon signed-rank test with n = 17 and a level of significance set at
P < .05 (see Table 4.3).
Table 4.2: Mean DDCT (and SEM) values for KLK1-15 in PA and NSGT specimens

KLK1

KLK2

KLK3

KLK4

Specimen

Mean DDCT

SEM

NSGT

1.000

0.620

PA

0.011

0.008

NSGT

1.000

0.403

PA

0.060

0.029

NSGT

1.000

0.345

PA

0.090

0.046

NSGT

1.000

0.426
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KLK5

KLK6

KLK7

KLK8

KLK9

KLK10

KLK11

KLK12

KLK13

PA

0.092

0.050

NSGT

1.000

0.449

PA

3.550

2.646

NSGT

1.000

0.497

PA

1.219

0.851

NSGT

1.000

0.403

PA

3.183

2.286

NSGT

1.000

0.372

PA

0.831

0.443

NSGT

1.000

0.243

PA

0.575

0.280

NSGT

1.000

0.266

PA

0.984

0.489

NSGT

1.000

0.234

PA

0.285

0.130

NSGT

1.000

0.361

PA

0.287

0.142

NSGT

1.000

0.319

PA

0.144

0.076
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KLK14

KLK15

NSGT

1.000

0.395

PA

0.602

0.357

NSGT

1.000

0.317

PA

0.218

0.130

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue;
KLK, kallikrein; DDCT, relative quantitation value; SEM, standard error of the
mean.
Table 4.3: Wilcoxon signed-rank test using paired DCT values for KLK1-15 in PA
and NSGT specimens
KLK

n

P-value

KLK1

17

0.0114*

KLK2

17

0.9045

KLK3

17

0.0500

KLK4

17

0.6171

KLK5

17

0.0751

KLK6

17

0.7566

KLK7

17

0.0500

KLK8

17

0.8337

KLK9

17

0.0688

KLK10

17

0.9045
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KLK11

17

0.4065

KLK12

17

0.0444*

KLK13

17

0.0278*

KLK14

17

0.2670

KLK15

17

0.0549

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue;
KLK, kallikrein. *P < .05

4.1.3

Graphical presentation of the data

The data points from Table 4.2 were used to plot the relative levels of mean KLK mRNA
for the 17 paired PA and NSGT samples (see Figs. 4.1-4.15). It should be noted that mean
DDCT (and SEM) values were used to plot Figs. 4.1-4.15; statistical calculations were
based on individual DCT values (see Table 4.3) and the asterisks in Figs. 4.1, 4.12 and 4.13
denote statistical significance (P < .05).
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Figure 4.1: Relative levels of mean mRNA expression for KLK1 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue. *P < .05

Figure 4.2: Relative levels of mean mRNA expression for KLK2 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.
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Figure 4.3: Relative levels of mean mRNA expression for KLK3 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.

Figure 4.4: Relative levels of mean mRNA expression for KLK4 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.
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Figure 4.5: Relative levels of mean mRNA expression for KLK5 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.

Figure 4.6: Relative levels of mean mRNA expression for KLK6 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.
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Figure 4.7: Relative levels of mean mRNA expression for KLK7 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.

Figure 4.8: Relative levels of mean mRNA expression for KLK8 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.
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Figure 4.9: Relative levels of mean mRNA expression for KLK9 in PA specimens and
NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK, kallikrein;
PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.

Figure 4.10: Relative levels of mean mRNA expression for KLK10 in PA specimens
and NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK,
kallikrein; PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.
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Figure 4.11: Relative levels of mean mRNA expression for KLK11 in PA specimens
and NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK,
kallikrein; PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.

Figure 4.12: Relative levels of mean mRNA expression for KLK12 in PA specimens
and NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK,
kallikrein; PA, pleomorphic adenoma; NSGT, normal salivary gland tissue. *P < .05
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Figure 4.13: Relative levels of mean mRNA expression for KLK13 in PA specimens
and NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK,
kallikrein; PA, pleomorphic adenoma; NSGT, normal salivary gland tissue. *P < .05

Figure 4.14: Relative levels of mean mRNA expression for KLK14 in PA specimens
and NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK,
kallikrein; PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.
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Figure 4.15: Relative levels of mean mRNA expression for KLK15 in PA specimens
and NSGT controls. Abbreviations: mRNA, messenger ribonucleic acid; KLK,
kallikrein; PA, pleomorphic adenoma; NSGT, normal salivary gland tissue.

4.2 Immunohistochemical analysis
4.2.1
4.2.1.1

Experimental results
Negative control samples for immunostaining

All PA and NSGT specimens were preliminarily subjected to the immunostaining protocol
in the absence of KLK-specific primary antibody (i.e., KLK1, KLK12, KLK13 or KLK8
polyclonal antibodies) (see Table 3.4). Representative negative control slides are shown in
Figs. 4.16 and 4.17.
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Figure 4.16: Negative immunostaining for KLKs in PA specimen from Case 2
(original magnification ´200).

Figure 4.17: Negative immunostaining for KLKs in NSGT specimen from Case 2
(original magnification ´200).
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4.2.1.2

Determination of KLK-specific antibody dilution

To determine the appropriate dilution for KLK-specific polyclonal antibodies (see Table
3.5), sections of KLK-rich tissues (i.e., prostate gland or skin) [122, 136, 172, 187, 189,
208, 221, 222] were processed using the immunostaining protocol (see Section 3.3.3). The
resulting positive control slides for KLK1, KLK12, KLK13 and KLK8 are shown in Figs.
4.18-4.21.

Figure 4.18: Positive immunostaining for KLK1 (brown staining in cytoplasm of cells)
in healthy prostate gland (original magnification ´200).
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Figure 4.19: Positive immunostaining for KLK12 (brown staining in cytoplasm of
cells) in healthy skin (original magnification ´200).

Figure 4.20: Positive immunostaining for KLK13 (brown staining in cytoplasm of
cells) in healthy skin (original magnification ´200).
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Figure 4.21: Positive immunostaining for KLK8 (brown staining in cytoplasm of cells)
in healthy skin (original magnification ´200).

4.2.1.3

Immunostaining for KLK1 in PA and NSGT

Using the calculated dilution of 1/1000 for the KLK1 polyclonal antibody (see Table 3.5),
PA and NSGT specimens were subjected to the immunostaining protocol. Representative
slides are shown in Figs. 4.22 and 4.23.
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Figure 4.22: Immunostaining for KLK1 (brown staining in cytoplasm of cells) in PA
specimen from Case 13 (original magnification ´200).

Figure 4.23: Immunostaining for KLK1 (brown staining in cytoplasm of cells) in
NSGT specimen from Case 13 (original magnification ´200).
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4.2.1.4

Immunostaining for KLK12 in PA and NSGT

Using the calculated dilution of 1/100 for the KLK12 polyclonal antibody (see Table 3.5),
PA and NSGT specimens were subjected to the immunostaining protocol. Representative
slides are shown in Figs. 4.24 and 4.25.

Figure 4.24: Immunostaining for KLK12 (brown staining in cytoplasm of cells) in PA
specimen from Case 8 (original magnification ´200).
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Figure 4.25: Immunostaining for KLK12 (brown staining in cytoplasm of cells) in
NSGT specimen from Case 8 (original magnification ´200).

4.2.1.5

Immunostaining for KLK13 in PA and NSGT

Using the calculated dilution of 1/2000 for the KLK13 polyclonal antibody (see Table 3.5),
PA and NSGT specimens were subjected to the immunostaining protocol. Representative
slides are shown in Figs. 4.26 and 4.27.
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Figure 4.26: Immunostaining for KLK13 (brown staining in cytoplasm of cells) in PA
specimen from Case 7 (original magnification ´200).

Figure 4.27: Immunostaining for KLK13 (brown staining in cytoplasm of cells) in
NSGT specimen from Case 7 (original magnification ´200).

69

4.2.1.6

Immunostaining for KLK8 in PA and NSGT

Using the calculated dilution of 1/200 for the KLK8 polyclonal antibody (see Table 3.5), a
random selection of 5 paired PA and NSGT specimens were subjected to the
immunostaining protocol. Representative slides are shown in Figs. 4.28 and 4.29.
It should be noted that PA specimens used for immunostaining did not show a statistically
significant alteration in KLK8 expression relative to NSGT (see Table 4.3). The intention
was to compare staining immunoreactivity scores for the dysregulated KLKs (i.e., KLK1,
KLK12 and KLK13) with those for a non-dysregulated KLK (i.e., KLK8).

Figure 4.28: Immunostaining for KLK8 (brown staining in cytoplasm of cells) in PA
specimen from Case 12 (original magnification ´200).

70

Figure 4.29: Immunostaining for KLK8 (brown staining in cytoplasm of cells) in
NSGT specimen from Case 12 (original magnification ´200).

4.2.1.7

Evaluation of immunostaining

A semi-quantitative analysis of the immunostained slides was performed under light
microscopy according to previously described techniques [236, 238]. Staining
immunoreactivity scores were assigned using the scoring system outlined in Tables 3.6 and
3.7, and the results are shown in Tables 4.4-4.7.

71

Table 4.4: Staining immunoreactivity scores for KLK1 in PA and NSGT specimens
Case No.

1

2

3

4

5

6

7

8

Ductal cells

Non-ductal cells

Prop

Int

OSS

Prop

Int

OSS

PA

3

2

5

3

1

4

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7
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9

10

11

12

13

14

15

16

17

18

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

3

2

5

3

1

4

NSGT

5

3

8

5

2

7

PA

3

2

5

3

1

4

NSGT

5

3

8

4

1

5

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

5

3

8

5

2

7

NSGT

5

3

8

5

2

7

PA

4

2

6

4

2

6

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

3

2

5

3

1

4

NSGT

5

3

8

5

1

6

PA

5

2

7

5

1

6
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19

20

21

22

23

24

25

26

NSGT

5

2

7

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

3

8

PA

4

2

6

5

1

6

NSGT

4

3

7

4

2

6

PA

4

1

5

4

1

5

NSGT

5

2

7

5

1

6

PA

5

2

7

5

2

7

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

5

2

7

5

2

7

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

3

8

PA

4

2

6

4

2

6

NSGT

5

3

8

5

2

7

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Prop,
proportion score; Int, intensity score; OSS, overall staining score.
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Table 4.5: Staining immunoreactivity scores for KLK12 in PA and NSGT specimens
Case No.

1

2

3

4

5

6

7

8

Ductal cells

Non-ductal cells

Prop

Int

OSS

Prop

Int

OSS

PA

3

1

4

3

1

4

NSGT

5

2

7

5

1

6

PA

3

2

5

3

1

4

NSGT

4

2

6

4

1

5

PA

2

2

4

2

1

3

NSGT

5

2

7

4

1

5

PA

3

2

5

3

1

4

NSGT

4

3

7

4

2

6

PA

3

1

4

3

1

4

NSGT

4

3

7

4

2

6

PA

3

1

4

3

1

4

NSGT

5

2

7

5

1

6

PA

3

2

5

3

1

4

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

4

2

6
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9

10

11

12

13

14

15

16

17

18

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT*

n/a

n/a

n/a

n/a

n/a

n/a

PA

4

2

6

3

1

4

NSGT

4

2

6

2

1

3

PA

4

2

6

3

1

4

NSGT

4

3

7

4

2

6

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

4

1

5

4

1

5

NSGT

5

3

8

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

3

2

5

3

1

4

NSGT

5

3

8

5

1

6

PA

5

2

7

5

1

6

76

19

20

21

22

23

24

25

26

NSGT

5

2

7

5

2

7

PA

5

2

7

5

1

6

NSGT

5

3

8

5

3

8

PA

3

2

5

3

1

4

NSGT*

n/a

n/a

n/a

n/a

n/a

n/a

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

3

2

5

3

2

5

NSGT

5

2

7

3

1

4

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

2

6

NSGT

4

2

6

4

1

5

PA

5

2

7

5

1

6

NSGT

5

3

8

5

2

7

PA

2

1

3

2

1

3

NSGT

4

2

6

4

2

6

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Prop,
proportion score; Int, intensity score; OSS, overall staining score. *No identifiable NSGT
on slide.
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Table 4.6: Staining immunoreactivity scores for KLK13 in PA and NSGT specimens
Case No.

1

2

3

4

5

6

7

8

Ductal cells

Non-ductal cells

Prop

Int

OSS

Prop

Int

OSS

PA

4

3

7

4

2

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

4

2

6

4

2

6

NSGT

5

3

8

5

3

8

PA

4

2

6

4

1

5

NSGT

5

3

8

5

3

8

PA

4

2

6

4

1

5

NSGT

5

3

8

5

3

8

PA

4

2

6

4

1

5

NSGT

5

3

8

5

3

8

PA

4

2

6

3

1

4

NSGT

5

3

8

5

3

8

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

78

9

10

11

12

13

14

15

16

17

18

PA

4

2

6

4

1

5

NSGT

5

3

8

5

3

8

PA

4

3

7

4

2

6

NSGT*

n/a

n/a

n/a

n/a

n/a

n/a

PA

5

3

8

5

2

7

NSGT

5

3

8

5

2

7

PA

3

2

5

3

1

4

NSGT

4

3

7

4

2

6

PA

4

2

6

3

1

4

NSGT

5

3

8

5

3

8

PA

5

2

7

4

2

6

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

3

8

5

3

8

PA

5

2

7

4

1

5

NSGT

5

3

8

5

3

8

PA

3

2

5

3

1

4

NSGT

5

3

8

4

2

6

PA

5

3

8

5

2

7

79

19

20

21

22

23

24

25

26

NSGT

5

3

8

5

3

8

PA

3

2

5

3

1

4

NSGT

5

3

8

5

2

7

PA

5

3

8

3

1

4

NSGT*

n/a

n/a

n/a

n/a

n/a

n/a

PA

5

2

7

5

1

6

NSGT

5

2

7

5

2

7

PA

5

2

7

4

2

6

NSGT

5

3

8

5

2

7

PA

5

3

8

5

2

7

NSGT

5

3

8

5

3

8

PA

5

2

7

5

2

7

NSGT

5

3

8

5

2

7

PA

5

3

8

5

2

7

NSGT

5

3

8

5

2

7

PA

4

1

5

4

1

5

NSGT

5

3

8

5

3

8

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Prop,
proportion score; Int, intensity score; OSS, overall staining score. *No identifiable NSGT
on slide.
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Table 4.7: Staining immunoreactivity scores for KLK8 in PA and NSGT specimens
Case No.

2

6

9

10

12

20

Ductal cells

Non-ductal cells

Prop

Int

OSS

Prop

Int

OSS

PA

4

2

6

4

1

5

NSGT

5

3

8

5

2

7

PA

4

2

6

4

1

5

NSGT

5

2

7

5

2

7

PA

4

2

6

4

1

5

NSGT

4

3

7

4

2

6

PA

5

3

8

5

2

7

NSGT*

n/a

n/a

n/a

n/a

n/a

n/a

PA

4

2

6

4

2

6

NSGT

5

3

8

5

2

7

PA

5

3

8

5

2

7

NSGT

5

3

8

5

2

7

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Prop,
proportion score; Int, intensity score; OSS, overall staining score. *No identifiable NSGT
on slide.

4.2.2

Statistical analysis

The OSS values for KLK1, KLK12, KLK13 and KLK8 in PA and NSGT specimens were
subjected to Wilcoxon signed-rank tests with the level of significance set at P < .05. The
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corresponding median OSS values and interquartile ranges were determined for both ductal
cells and non-ductal cells for each specimen (see Tables 4.8-4.11).
Table 4.8: Wilcoxon signed-rank test for KLK1 immunostaining in PA and NSGT
specimens
Ductal cells
n

Mdn

IQR

Non-ductal cells
P-value

n

OSS
PA

Mdn

IQR

P-value

<.0001*

OSS

26

7

6-7

NSGT 26

8

8-8

<.0001*

26

6

5-6

26

7

7-8

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Mdn,
median; OSS, overall staining score; IQR, interquartile range. *P < .05
Table 4.9: Wilcoxon signed-rank test for KLK12 immunostaining in PA and NSGT
specimens
Ductal
n

Mdn

IQR

Non-ductal
P-value

n

OSS
PA

24

NSGT 24

Mdn

IQR

P-value

0.0001*

OSS

5.5

5-6

7

7-8

<.0001*

24

4

4-5

24

6

5.25-7

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Mdn,
median; OSS, overall staining score; IQR, interquartile range. *P < .05
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Table 4.10: Wilcoxon signed-rank test for KLK13 immunostaining in PA and NSGT
specimens
Ductal
n

Mdn

IQR

Non-ductal
P-value

n

OSS
PA

Mdn

IQR

P-value

< .0001*

OSS

24

6

6-7

NSGT 24

8

8-8

0.0001*

24

5

5-6

24

7.5

7-8

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Mdn,
median; OSS, overall staining score; IQR, interquartile range. *P < .05
Table 4.11: Wilcoxon signed-rank test for KLK8 immunostaining in PA and NSGT
specimens
Ductal
n

Mdn

IQR

Non-ductal
P-value

n

OSS

Mdn

IQR

P-value

0.1250

OSS

PA

5

6

6-7

NSGT

5

8

7-8

0.1250

5

5

5-6.5

5

7

6.5-7

Abbreviations: PA, pleomorphic adenoma; NSGT, normal salivary gland tissue; Mdn,
median; OSS, overall staining score; IQR, interquartile range.

4.3 Capsular invasion and/or perforation
4.3.1

Analysis of original diagnostic histology slides

The original histology slides used for diagnosing PA in cases 1-26 were analyzed for
evidence of capsular invasion and/or perforation. Only the cases which met the selection
criteria for this study (see Section 3.1.3) were analyzed (see Tables 4.12 and 4.13). Overall,
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8 cases demonstrated capsular invasion and 8 cases displayed capsular perforation. It
should be noted that case 17 was omitted from Tables 4.12 and 4.13 as it displayed neither
capsular invasion nor capsular perforation. Case 25 was the only case with a positive
surgical margin, which indicated a higher risk for tumor recurrence.
Table 4.12: Histology slides demonstrating PA capsular invasion
Case

Met selection
criteria?

5

Yes

7

Yes

10

Yes

11

Yes

12

Yes

15

Yes

16

Yes

18

Yes

20

No

14

No

26

No

Abbreviations: PA, pleomorphic adenoma.
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Table 4.13: Histology slides demonstrating PA capsular perforation
Case

Met selection
criteria?

1

No

2

Yes

3

Yes

4

Yes

6

Yes

8

Yes

9

Yes

13

Yes

19

Yes

21

No

22

No

23

No

24

No

25

No

Abbreviations: PA, pleomorphic adenoma.
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Representative slides were chosen to demonstrate each type of capsular violation (see Figs.
4.30-4.33). A thick, intact capsule was found on the histology slide for case 21 (see Fig.
4.30). Invasion of PA into the fibrous capsule was shown on the histology slide for case 20
(see Fig. 4.31). Perforation of PA through the capsule was identified on the histology slide
for case 21 (see Fig. 4.32). Of all cases, only case 25 had a positive surgical margin as
shown in Fig. 4.33.

Figure 4.30: Haematoxylin-eosin stain for Case 21 showing pleomorphic adenoma
(black arrow), intact fibrous capsule (white triangle) and normal salivary gland tissue
(white arrow) (original magnification ´50).

86

Figure 4.31: Haematoxylin-eosin stain for Case 20 showing invasion of pleomorphic
adenoma (black arrow) into fibrous capsule (original magnification ´50).
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Figure 4.32: Haematoxylin-eosin stain for Case 21 showing perforation of
pleomorphic adenoma (black arrow) through fibrous capsule (original magnification
´50).
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Figure 4.33: Haematoxylin-eosin stain for Case 25 showing ink markings (black
arrow) on pleomorphic adenoma margin (original magnification ´50).

Surgical pathology reports for cases 1-26 were examined to determine PA specimen sizes;
these values were then compared with the presence or absence of capsular violation (i.e.,
invasion and/or perforation) (see Table 4.14).
Table 4.14: PA specimen size and pattern of capsular violation
Case

Size (cm3)

Capsular
violation

1

0.040

Perforation

2

12.00

Perforation

3

1.20

Perforation
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4

3.09

Perforation

5

0.66

Invasion

6

5.76

Perforation

7

1.45

Invasion

8

2.02

Perforation

9

10.08

Perforation

10

2.25

Invasion

11

1.30

Invasion

12

1.62

Invasion

13

1.80

Perforation

14

1.20

Invasion

15

0.43

Invasion

16

5.28

Invasion

17

n/a

n/a

18

10.03

Invasion

19

5.76

Perforation

20

57.75

Invasion

21

4.32

Perforation

22

n/a

n/a
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23

2.25

Perforation

24

3.96

Perforation

25

3.00

Perforation

26

3.83

Invasion

Abbreviations: PA, pleomorphic adenoma.

4.3.2

Statistical analysis

The KLK1, KLK12 and KLK13 DCT values (not shown) for PA cases with capsular invasion
were compared to the DCT values for cases with capsular perforation. A Mann-Whitney U
test was performed to compare the unpaired KLK1, KLK12 and KLK13 DCT values for the
various PA cases (see Table 4.15). Likewise, a Mann-Whitney U test was employed for
comparison of the OSS values for ductal cells (see Table 4.16) and non-ductal cells (see
Table 4.17) in the various PA cases showing capsular violation (i.e., invasion and/or
perforation). Finally, surgical pathology reports were examined to retrieve PA specimen
size so that associations with capsular violation could be determined (see Table 4.18). The
level of significance for all statistical tests was set at P < .05.
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Table 4.15: Mann-Whitney U test comparing KLK1, KLK12 and KLK13 mRNA levels
in PA cases with capsular invasion and/or perforation
Capsular violation

Mean mRNA level

P-value

(SEM)
KLK1

Invasion (n = 8)

8.528 (1.550)

Perforation (n = 8)

0.071 (5.499)

KLK12 Invasion (n = 8)
Perforation (n = 8)
KLK13 Invasion (n = 8)
Perforation (n = 8)

13.570 (0.828)

0.2345

0.0830

11.290 (0.651)
10.050 (5.408)

0.5737

9.411 (5.191)

Abbreviations: PA, pleomorphic adenoma; KLK, kallikrein; mRNA, messenger
ribonucleic acid; SEM, standard error of the mean.
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Table 4.16: Mann-Whitney U test comparing KLK1, KLK12 and KLK13
immunostaining in ductal cells of PA cases with capsular invasion and/or perforation
Capsular violation
KLK1

Mdn OSS (IQR)

P-value

Invasion (n = 11)

6 (6-7)

0.0135*

Perforation (n = 14)

7 (7-7)

KLK12 Invasion (n = 9)
Perforation (n = 14)
KLK13 Invasion (n = 9)
Perforation (n = 14)

5 (4.5-6)

0.3170

6 (4.75-7)
6 (5.5-7.5)

0.9159

6 (6-7)

Abbreviations: PA, pleomorphic adenoma; KLK, kallikrein; OSS, overall staining score;
IQR, interquartile range. *P < .05
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Table 4.17: Mann-Whitney U test comparing KLK1, KLK12 and KLK13
immunostaining in non-ductal cells of PA cases with capsular invasion and/or
perforation
Capsular violation
KLK1

Invasion (n = 11)
Perforation (n = 14)

KLK12 Invasion (n = 9)
Perforation (n = 14)
KLK13 Invasion (n = 9)
Perforation (n = 14)

Mdn OSS (IQR)

P-value

6 (5-6)

0.0470*

6 (6-6.25)
4 (4-5.5)

0.4094

5 (4-6)
5 (4.5-6.5)

0.5961

5.5 (5-6.25)

Abbreviations: PA, pleomorphic adenoma; KLK, kallikrein; OSS, overall staining score;
IQR, interquartile range. *P < .05
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Table 4.18: Mann-Whitney U test comparing specimen size between PA cases with
capsular invasion and/or perforation
Capsular

Mean size

SEM

violation

(cm3)

(cm3)

7.800

5.065

4.252

0.960

Invasion

P-value

0.3238

(n = 11)
Perforation
(n = 13)
Abbreviations: PA, pleomorphic adenoma; SEM, standard error of the mean.

4.4 Clinical outcomes
4.4.1

Tumor recurrence and/or malignant transformation

After the 1-year postoperative follow-up visit, all study subjects had been discharged back
to the care of their family physician with instructions to return to the surgeon with any new
concerns or suspicious masses. Review of each subject’s electronic health record on
October 22nd, 2017, revealed no PA recurrences or malignant transformation (i.e.,
carcinoma ex PA) over the 10-year postoperative period.
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Chapter 5

5

Discussion

5.1 Interpretation of results
Our RT-qPCR experiments revealed a statistically significant decrease in mRNA
expression for KLK1, KLK12 and KLK13 in PA relative to NSGTs. In contrast, there were
no statistically significant differences in KLK2-11, KLK14 and KLK15 expression between
PA and NSGT specimens. These findings were corroborated using immunohistochemical
analyses, which showed a statistically significant decrease in staining immunoreactivity
scores (i.e., OSS) for KLK1, KLK12 and KLK13 in ductal and non-ductal cells of PA and
NSGT specimens. No statistically significant differences were observed for KLK8
immunostaining in ductal and non-ductal cells of PA and NSGT specimens. It should be
noted that KLK8 had been arbitrarily selected from the non-dysregulated KLKs to contrast
with the immunostaining for dysregulated KLK proteins. Based on the immunostaining
analyses, it was evident that median OSS values for PA specimens were greater in ductal
cells than in non-ductal cells, which was consistent with previous observations in the
literature [202, 206, 223]. No stromal staining was observed for any of the PA specimens.
Comparison of KLK1, KLK12 and KLK13 mRNA levels in PA specimens with different
capsular violation phenomena (i.e., invasion and/or perforation) demonstrated no
statistically significant differences; however, analysis of KLK1, KLK12 and KLK13
proteins in ductal cells and non-ductal cells of PA specimens showed a statistically
significant increase in median OSS and IQR values for KLK1 in cases with capsular
perforation. This finding may suggest that PAs with relatively increased KLK1 protein
levels are more aggressive, with a greater incidence of fibrous capsule perforation;
however, the fact that all PAs were subjected to preoperative FNA makes it more likely
that capsular violation was artefactual.
Consideration of the various PA specimen sizes prompted us to investigate correlations
between tumor size and the presence or absence of capsular violation. Since PA is a slowly
growing benign tumor, we surmised that larger tumors would not be more likely to
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perforate the fibrous capsule; conversely, some PAs may have more aggressive
characteristics, which allow faster growth and capsular violation. Our investigations
demonstrated no statistically significant differences in tumor size between PAs with
capsular invasion and/or perforation. Again, these findings support the likelihood that
capsular violation phenomena were artefactual features produced during preoperative
FNA.
Review of the medical records for each subject was performed to determine the number of
cases with tumor recurrence or malignant transformation. At the 10-year follow-up mark,
none of the 26 PA cases had a documented tumor recurrence or malignant transformation.
It should be noted that 3 of the 26 cases had died due to unrelated causes during the 10year postoperative period. Only case 25 had histologic confirmation of positive tumor
margins, yet this case did not present with tumor recurrence or malignant transformation.
These findings are consistent with the decreased recurrence rates for modern surgical
treatment of PA (i.e., partial superficial parotidectomy/complete submandibular gland
excision vs. simple enucleation) and the low incidence of malignant transformation.

5.2 Summary of common locations and known functions of
KLK1, KLK12 and KLK13
Kallikrein-1 is most abundant in the pancreas and salivary glands, followed by the colon
and the small intestine [122]. Lower concentrations are found in esophagus, kidney, lymph
node, prostate, stomach, thyroid, ureter, and vaginal tissues [122]. In normal physiology,
KLK1 is involved in the tissue kallikrein-kinin system (KKS)¾a system regarded as one
of the main mechanisms controlling systemic and local hemodynamics. Recent studies
have implicated this system in protection from hypertension, vascular remodeling and renal
fibrosis. The KKS is comprised of kallikreins (kinin-forming enzymes), kininogens
(substrates), kinins (vasoactive peptides), kinin-degrading enzymes and kinin receptors
[226]. Of the 15 KLKs, only KLK1 contributes to formation of bradykinin (BK) and lysbradykinin (lys-BK or kallidin). Plasma kallikrein, which was once considered a
coagulation factor, is required for the formation of BK in blood but differs from KLK1 in
both molecular weight and immunological characteristics [227]. Plasma kallikrein mainly
induces fibrinolysis but also activates neutrophils and C3 convertase. Kallikrein-1 from
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vascular or extravascular sources cleaves kinins from the substrate kininogen (KNG),
which is found on endothelial cell membranes and dispersed within circulating blood. The
bradykinin B2 and B1 receptors, which are constitutively expressed in endothelial cells and
induced under stress conditions, respectively, are both activated by kinin. These kinin
receptors can interact and compensate for one another; furthermore, they can form
heterodimers with other receptors, including angiotensin II receptor type 1 (AT1). Because
the B2 receptors and AT1 receptors are functional antagonists in cardiovascular regulation,
the heterodimeric complex between them is postulated to play a role in blood pressure
control [228, 229]. When this heterodimer forms and binds to endothelial cells, the
vasodilator activity of bradykinin is reduced and the vasoconstrictor activity of angiotensin
II is enhanced. Kallikrein-1 is constitutively expressed by endothelial cells and it is released
upon endothelial cell activation to digest the vascular basement membrane and interstitial
matrix. These processes are necessary for migration, vascular sprouting and angiogenesis.
Considering the observed downregulation of KLK1 mRNA and protein level expression in
our study using PA specimens, the non-invasive, benign nature of PA could in part be
explained by the above-mentioned phenomena. In the presence of decreased KLK1 levels,
there may be a reduced rate of vascular basement membrane and interstitial matrix
digestion, resulting in slower tumor growth and a lower incidence of invasion as seen with
PA.
The results of airway disease research involving KLK1 may provide mechanistic
information for the pathophysiological processes at play in PA. Kallikrein-1 is the primary
kinin-generating enzyme of the airways and its involvement in the pathophysiology of
reactive airway disease raised questions surrounding its utility as a therapeutic target.
Asthma is associated with a hyperactivation of bradykinin B2 receptors, which are known
to be activated by KLK1-mediated kinin production [226]. In samples of bronchial alveolar
lavage fluid from individuals with asthma or chronic bronchitis, KLK1 levels are
consistently elevated, especially after exposure to allergens or bronchoconstrictive stimuli.
When KLK1-mediated kinin production occurs, the bradykinin B2 receptors are activated
and induce bronchoconstriction and mucus hypersecretion. The possible pathological role
of increased KLK1 activity in asthma has been further reinforced through several reports
demonstrating correlations with interleukin-8 and free bradykinin in bronchial alveolar
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lavage fluid [230]. Increased KLK1 activity levels in airway disease are thought to result
from KLK1 secretion by activated alveolar macrophages and neutrophils [231]. Moreover,
the KLK1 stored in apical airway epithelial cells, which is immobilized and inhibited by
hyaluronic acid (HA), is released in asthma by reactive oxygen species-induced HA
breakdown. The disinhibition of tissue KLK1 activates pro-epidermal growth factor (proEGF) in human airway goblet cells, ultimately resulting in the release of mature EGF.
Binding of EGF to the EGF receptor results in mucus hypersecretion and goblet cell
hyperplasia¾two of the characteristic features of chronic bronchitis. The development
and application of KLK1 inhibitors, such as KLK1-specific antibodies, have shown
substantial inhibition of airway hyperresponsiveness and late-phase allergen-induced
bronchoconstriction in preliminary studies [232]. These findings suggest a possible
application of KLK1 inhibitors in the treatment of asthma and chronic bronchitis. By
extension of these findings, it stands to reason that the decreased levels of KLK1 in PA
specimens may result in similar processes to those observed with KLK1 inhibition in
chronic bronchitis and asthma; specifically, decreased KLK1 expression may result in
reduced KLK1-mediated kinin production, reduced bradykinin B2 receptor activation, and
thus decreased smooth muscle contraction (i.e., myoepithelial cells) and saliva secretion.
It is possible that decreased saliva secretion in PA-positive salivary gland tissue may
facilitate formation of the observed mucoid/myxoid and chondroid stroma commonly
found in PA, especially if the proportion of serous-to-mucous saliva is altered in this tumor.
Further studies would be required to identify the above-mentioned phenomena.
Outside of the airways, KLK1 is a key player in the renal system. This enzyme is secreted
into the lumina of the renal collecting tubules, where it regulates numerous apical
transporters. Kallikrein-1 activates sodium channels in the renal epithelial cells, resulting
in inhibition of cortical collecting duct H+, K+-ATPase and activation of transient receptor
potential vanilloid channels [233-235]. A special function of KLK1 is protection against
hyperkalemia after excess dietary potassium intake via rapid, aldosterone-independent
potassium excretion (i.e., kaliuresis) [236]. These findings were corroborated by studies
showing that KLK1-knockout mice demonstrated cardiovascular abnormalities and
deficiencies in renal tubular absorption [237]. A human KLK1 polymorphism, A1789G, is
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associated with an increased risk for stenosis of the coronary arteries [238], while another
polymorphism in exon 3 of KLK1 has been linked to hypertension-independent arterial
dysfunction via decreased KLK1 activity [239]. When human KLK1 is delivered by an
adenoviral vector, mice and human subjects have gained protection against systemic lupus
erythematosus and glomerular basement membrane (GBM)-specific-antibody-induced
nephritis [240, 241]. Confirmation of this result was achieved by showing that antagonism
of the KLK1 pathway augmented symptoms of GBM-specific-antibody-induced nephritis,
whereas the severity of the disease was dampened using KLK1 agonists. Overall, these
studies have suggested that enhanced KLK1 activity is likely protective in cardiac and renal
injuries. The PAs in our study, which showed downregulation of KLK1 mRNA and protein
levels, may thus have lacked the protective benefits of KLK1. Decreased KLK1 expression
in PA may contribute to vascular dysfunction and altered electrolyte balance, which could
play a role in the pathophysiology of this tumor.
Kallikrein-related peptidase-12 is expressed in a variety of tissues, including salivary
gland, stomach, uterus, lung, thymus, prostate, colon, brain, breast, thyroid and trachea
[122]. Downregulation of KLK12 is observed in breast cancer tissues, but KLK12 is
upregulated by steroid hormones in cell lines for breast cancer and prostate cancer [242].
Certain endocrine gland-related malignant tumors have been associated with KLK12
protein dysregulation as well. One group of investigators evaluated the effects of KLK12
mRNA and protein downregulation on the cell cycle and proliferation of AGS cells¾a
human gastric adenocarcinoma cell line [243]. The observed KLK12 mRNA and protein
expression levels were higher in AGS cells than the GES-1 normal gastric epithelial cells.
Transfection of AGS cells with KLK12 siRNA led to downregulation of KLK12 mRNA
and protein expression, reduced cell proliferation, and lower cell counts with respect to the
negative control. Kallikrein-related peptidase-12 siRNA increased the number of AGS
cells in G0/G1 and reduced those in S phase of the cell cycle. Moreover, downregulation
of KLK12 in AGS cells decreased their ability to penetrate the membrane in a migration
assay. Overall, KLK12 siRNA inhibited the proliferation and migration of AGS gastric
cancer cells and caused their arrest in the G0/G1 phase of the cell cycle. Given the
decreased KLK12 mRNA and protein expression in PA, similar processes to those
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observed in AGS gastric cancer cells may occur in this benign, slow-growing tumor. The
downregulation of KLK12 in PA could thus account for its slow rate of growth and low
incidence of invasion.
The proteolytic regulation of skin desquamation by KLKs is necessary for epidermal
barrier function, and elevated levels of KLKs, including KLK12 and KLK13, have been
reported in diseases of the skin. The known KLK inhibitor, serine protease inhibitor of
Kazal-type 6 (SPINK6), is present in the human stratum corneum [244, 245]. A group of
investigators revealed that recombinant SPINK6 efficiently inhibited mouse KLK5 and
human KLK2, KLK4-7, KLK12, KLK13 and KLK14, whereas human KLK1 and KLK8
were not inhibited [246]. Stimulation of cultured mouse keratinocytes with flagellin, EGF,
and IL-1b did not alter SPINK6 expression, whereas stimulation with TNF-a, IFN-g and
all-trans retinoic acid caused significant downregulation of SPINK6. Overall, these
researchers demonstrated that mechanically and metabolically induced skin barrier
dysfunction resulted in downregulation of SPINK6, a potent inhibitor of KLKs, including
KLK12 and KLK13. These findings suggested that upregulation of KLK12 and KLK13,
among other KLKs, may be associated with disease states of the skin. By extension, it is
possible that SPINK6 activity in PA accounts for the observed downregulation of KLK12
and KLK13 mRNA and proteins. Inhibition of KLK12 and KLK13 by SPINK6 may be
involved in the pathophysiology of PA but further studies are required to identify such
phenomena.
Several tissue KLKs, including KLK12, are significantly dysregulated at the mRNA level
in lung cancer and can be detected in human serum [247, 248]. A recent study comparing
the sera of healthy subjects and subjects with non-small cell lung cancer (NSCLC) found
significantly lower levels of KLK5, KLK7, KLK8, KLK10 and KLK12 in the sera of
subjects with NSCLC; higher levels were observed for KLK11, KLK13 and KLK14 [248].
Only KLK11 and KLK12 were positively correlated with tumor stage. Overall, KLK11,
KLK12, KLK13 and KLK14 were associated with a higher risk of NSCLC, which
represented a potential serum panel of KLK biomarkers for lung cancer diagnosis. By
extrapolation of these findings, it seems plausible that decreased expression of KLK12 and
KLK13 in PA contribute to its low incidence of invasion and malignant transformation.
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Decreased KLK protein expression¾as observed in PA¾is not favorable for the
development of a diagnostic serum panel; however, the identification of a KLK profile for
PA may contribute to our overall understanding of the pathophysiology of salivary gland
tumors.
Expression of KLK13 has been found in a variety of both normal and diseased tissues [122,
249, 250]. In lung adenocarcinoma, significant upregulation of KLK13 mRNA has been
linked with increased malignant cell behavior; conversely, knockdown of endogenous
KLK13 gene expression was shown to cause a significant decrease in cell invasion and
migration [249]. Functional studies revealed that KLK13 is activated via demethylation of
its upstream region. The resulting elevation in KLK13 proteins enhanced the ability of
tumor cells to degrade extracellular laminin that, subsequently, facilitated cell metastatic
potential in an in vivo mouse model [249]. Another research group demonstrated that
KLK13 mRNA and immunohistochemical staining were significantly different in
malignant lung tissues (i.e., NSCLC) compared to adjacent healthy tissues [250].
Upregulation of KLK13 and KLK14 mRNA in tumors was independently associated with
a positive nodal status in subjects. Immunostaining results showed KLK13 and KLK14
localization in the cytoplasm of epithelial cells of normal bronchus and NSCLC.
Furthermore, positive immunostaining was significantly associated with adenocarcinoma
histotype for KLK13, and tumor size for KLK14. Subjects with elevated KLK13
expression at the mRNA or protein level had lower overall survival. Taken together, the
enhancing effects of KLK13 on tumor cell invasion and migration may allow it to serve as
a prognostic marker and a potential therapeutic target for lung cancer. By extension, these
findings may also help to explain the pathophysiology of PA, in which decreased KLK13
expression may contribute to the decreased incidence of invasion and malignant
transformation of this tumor.
The known sequestration of KLKs by serum protease inhibitors prompted researchers to
investigate the interaction of KLK13 with similar inhibitors [251]. Recombinant KLK13
produced in yeast was added to male and female sera and various biological fluids, and the
samples were analyzed with a KLK13 enzyme-linked immunosorbent assay (ELISA).
Enzymatically active KLK13 was labelled with I-125 and used for in vitro reactions with
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candidate protease inhibitors and serum samples. The identified inhibitors included a2antiplasmin, a2-macroglobulin and a1-antichymotrypsin. Another research group
revealed that members of the SPINK family regulate KLK activity through inhibition
[245]. These investigators found that SPINK6 exhibited inhibitory activity against KLK12
and KLK13, but not against KLK1, KLK3 and KLK11. Taken together, multiple KLK
inhibitors have been shown to independently regulate KLK13 activity and these findings
may help to explain the observed downregulation of KLK13 mRNA and proteins in PA.
In the oral cavity, KLK13 has been linked to burning mouth syndrome (BMS) [252].
Diagnosis of BMS is challenging for clinicians due to a lack of reliable methods for
establishing a definitive diagnosis. One research group used quantitative saliva proteomic
analysis to identify target proteins in BMS subjects’ saliva that may be used for simple,
non-invasive detection of the disease. Using ELISA measurements, three potential
biomarkers in human saliva were validated: a-enolase, IL-18 and KLK13. These findings
indicated that testing of the identified protein biomarkers in saliva may be a valuable
clinical tool for BMS detection. For such a tool to be used in the diagnosis or prognosis of
salivary gland tumors, a series of characteristic biomarkers for each tumor would need to
be identified and studied using multi-centered clinical trials. In doing so, it may be possible
to achieve multi-marker prediction models for rapid, convenient detection of salivary gland
tumors with high sensitivity and specificity; however, tumors with downregulated KLK
proteins (i.e., PA) would not be as easily detected using saliva or serum analyses.
Oral squamous cell carcinoma (OSCC) is another disease of the oral cavity that has been
linked to KLK13 dysregulation [253]. Researchers demonstrated by microarray analyses
that KLK13 was downregulated in OSCC. The expression of KLK13 in primary OSCCs
was evaluated and functional molecular experiments were performed in OSCC cell lines.
The findings included significantly decreased KLK13 expression compared to matched
normal counterparts. Moreover, KLK13-negative cases correlated significantly with
regional lymph node metastasis. In vitro, cells with upregulated KLK13 had decreased
invasiveness and motility as signified by upregulation of adhesions molecules (E-cadherin,
a-catenin, b-catenin, junction plakoglobin, plakophilin4, democollin2, desmoglein3, and
desmoplakin) compared to control cells. When KLK13-positive cells were transfected with
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siRNA against KLK13, the adhesion molecules were downregulated and the invasiveness
and migration activities were restored. These findings contradicted those of our study, in
that downregulation of KLK13 in PA appears to decrease the incidence of invasion and
metastasis; however, it is possible that currently unrecognized KLK cascades involved in
the pathogenesis of malignant tumors differ from those in benign tumors.
Kallikrein-related peptidase-13 is expressed by ductal epithelia and acinar cells in NSGT,
which prompted studies of its potential role in the pathogenesis of salivary gland tumors
[222]. Reports have linked KLK13 to malignant tumors and it was found to cleave the
major components of ECM, suggesting involvement in tissue remodeling and/or tumor
invasion and metastasis [254, 255]. A research group recently analyzed the expression
levels of KLK13 in benign and malignant salivary gland tumors [223]. Using
immunostaining analyses, normal tissues were compared to samples from PA, AdCC,
PLGA, ACC, MEC and ANOS. The results indicated that KLK13 expression was
upregulated in most salivary gland tumors. Immunostaining for KLK13 in PA was
significantly reduced relative to control samples. Conversely, immunostaining for KLK13
in PLGA, AdCC and ANOS was significantly increased relative to controls.
Mucoepidermoid carcinoma and ACC did not display much deviation in staining
immunoreactivity compared to healthy tissues. When ductal structures were assessed,
ductal cells and cells lining duct-like structures revealed more prominent immunostaining
intensity than non-ductal cells in most tumors. Overall, these investigators were the first to
report downregulation of KLK13 in PA. Our study corroborated these findings for PA and
additionally revealed downregulation of KLK13 mRNA compared to control tissues.
To date, our study is the first to identify statistically significant downregulation of KLK1,
KLK12 and KLK13 mRNA and proteins in PA specimens. Considering the variety of
diseases involving up- and downregulation of KLKs, our findings suggest the involvement
of a KLK cascade in the pathophysiology of PA; specifically, the downregulated
expression levels of KLK1, KLK12 and KLK13 may account for the low incidence of
invasion and malignant transformation of PA. The observed downregulation may involve
one or more KLK inhibitors, such as SPINK6, which has been shown to inhibit KLK12
and KLK13 but not KLK1; however, future work is required to identify such phenomena.
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5.3 Limitations and future work
The exploratory nature of this case-control study and the small number of specimens
utilized were major limitations. Although it was not the intention of this study to offer final
and conclusive solutions, the determination of a KLK profile for PA may help to establish
a causative link between KLK dysregulation and the pathophysiology of this tumor. The
results of our studies warrant further basic mechanistic studies and a large, multi-centered
prospective trial.
Other limitations in this study included the nature of the control tissues used. Analyzing
matched NSGTs from PA-containing glands (i.e., parotid gland or submandibular gland)
may have produced KLK mRNA and protein profiles which did not reflect those of healthy
salivary gland tissues. Local and systemic host factors that may have contributed to the
formation of PA may also have altered the KLK mRNA and protein expression in NSGTs.
Moving forward, salivary gland tissues from tumor-free glands (e.g., contralateral glands
or glands from healthy controls) should be compared to PA specimens.
The specificity of our IHC staining and the strength of our OSS method were limited by
the polyclonal nature of our KLK antibodies and the lack of blinding in the scoring process,
respectively. Regarding the KLK-specific primary antibodies, a greater staining specificity
may be obtained by using monoclonal antibodies; however, our options were limited to
polyclonal antibodies due to the sparse availability of monoclonal antibodies for KLK1,
KLK12, KLK13, and KLK8. The OSS method did not involve blinding of the observers to
the tissues being examined, which may have introduced observer bias. It should also be
noted that the small portions of PA and NSGTs provided by the surgical team did not allow
for the preparation of enough histology slides to repeat our IHC experiments. In future
studies, monoclonal KLK antibodies should be employed for greater staining specificity,
the scoring of immunostaining should be a blinded process, and all immunostaining
experiments should be repeated. Alternatively, immunofluorescence reactions may be
performed to allow for automatic quantitation of KLK proteins, which would eliminate
observer bias.

105

Future work may involve the development of a PA cell line, which could be utilized for
KLK-specific analyses. Assessment of PA cells subjected to adenoviral delivery of KLK1,
KLK12 and KLK13 genes may strengthen the findings of this study if transfected cells
demonstrated an increased incidence of invasion and/or malignant transformation.
Moreover, identification of KLK1, KLK12 and KLK13 inhibitors in PA may help to
explain the observed downregulation of these KLKs. Once KLK expression profiles for
other salivary gland neoplasms including MEC, PLGA, AdCC, ACC, ANOS and
carcinoma ex PA have been determined, a comparison of KLKs in PA and the malignant
tumors may be made. If the malignant tumors demonstrated increased levels of KLK1,
KLK12 and/or KLK13, it would be interesting to see how delivery of nanoliposomes
containing KLK1-, KLK12- and KLK13-targeting siRNA would affect tumor behavior.
Further investigations may involve the development of multiparametric panels of KLK
biomarkers for the diagnosis, prognosis and postoperative monitoring of various salivary
gland tumors, including PA. The overlapping histopathological features of salivary gland
tumors make it difficult to establish a diagnosis, especially when working with a limited
amount of tissue (e.g., preoperative FNA). For this reason, the additional information
gleaned from KLK-specific IHC staining of FNA samples may improve diagnostic
accuracy, which could greatly change the proposed management (e.g., simple enucleation
versus wide local excision). While the development of a simple and convenient serum or
saliva test may not be possible for PA due to the downregulation of KLK proteins in this
tumor, this foundational work may help to develop such tests for other salivary gland
tumors.
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Chapter 6

6

Conclusions

To date, our study is the first to identify statistically significant downregulation of KLK1,
KLK12 and KLK13 mRNA and proteins in PA by RT-qPCR and immunostaining,
respectively. For PA cases with capsular perforation and invasion, we identified no
statistically significant differences in KLK1, KLK12 or KLK13 mRNA expression;
however, a statistically significant increase in KLK1 protein was seen in ductal and nonductal cells of PAs with capsular perforation. We found no significant differences in tumor
size for PA cases with capsular violation (i.e., invasion and/or perforation). In the 10-year
postoperative period, no PA cases showed any recurrence or malignant conversion. Given
the variety of diseases involving up- and downregulation of KLKs, our findings suggest
the involvement of a KLK cascade in the pathophysiology of PA; specifically, the
decreased expression of KLK1, KLK12 and KLK13 mRNA and proteins may account for
the low incidence of invasion and/or malignant transformation of PA. This foundational
work may facilitate the development of clinically relevant applications for KLKs in the
diagnosis, prognosis and postoperative monitoring of PA. Ultimately, the development of
a simple and convenient serum or saliva test may benefit patients living in remote
communities with limited access to surgeons for biopsy or surgical follow-up.
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